CA3051652A1 - Glycopeptide derivatives for use in the treatment and/or prevention and/or attenuation of fibrosis diseases - Google Patents
Glycopeptide derivatives for use in the treatment and/or prevention and/or attenuation of fibrosis diseases Download PDFInfo
- Publication number
- CA3051652A1 CA3051652A1 CA3051652A CA3051652A CA3051652A1 CA 3051652 A1 CA3051652 A1 CA 3051652A1 CA 3051652 A CA3051652 A CA 3051652A CA 3051652 A CA3051652 A CA 3051652A CA 3051652 A1 CA3051652 A1 CA 3051652A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- use according
- mixture
- alkyl
- scars
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 42
- 206010016654 Fibrosis Diseases 0.000 title claims abstract description 35
- 230000004761 fibrosis Effects 0.000 title claims abstract description 35
- 238000011282 treatment Methods 0.000 title claims abstract description 22
- 230000002265 prevention Effects 0.000 title claims abstract description 20
- DQJCDTNMLBYVAY-ZXXIYAEKSA-N (2S,5R,10R,13R)-16-{[(2R,3S,4R,5R)-3-{[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-(ethylamino)-6-hydroxy-2-(hydroxymethyl)oxan-4-yl]oxy}-5-(4-aminobutyl)-10-carbamoyl-2,13-dimethyl-4,7,12,15-tetraoxo-3,6,11,14-tetraazaheptadecan-1-oic acid Chemical class NCCCC[C@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@@H](C)NC(=O)C(C)O[C@@H]1[C@@H](NCC)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DQJCDTNMLBYVAY-ZXXIYAEKSA-N 0.000 title description 5
- 150000001875 compounds Chemical class 0.000 claims abstract description 59
- 231100000241 scar Toxicity 0.000 claims abstract description 57
- 208000032544 Cicatrix Diseases 0.000 claims abstract description 54
- 230000037387 scars Effects 0.000 claims abstract description 54
- 208000002260 Keloid Diseases 0.000 claims abstract description 45
- 210000001117 keloid Anatomy 0.000 claims abstract description 45
- 230000001969 hypertrophic effect Effects 0.000 claims abstract description 32
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 21
- 239000000546 pharmaceutical excipient Substances 0.000 claims abstract description 5
- 239000000203 mixture Substances 0.000 claims description 47
- 229910052739 hydrogen Inorganic materials 0.000 claims description 17
- 150000003839 salts Chemical class 0.000 claims description 15
- 239000012453 solvate Substances 0.000 claims description 15
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 12
- 229910052731 fluorine Inorganic materials 0.000 claims description 10
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 10
- 239000001257 hydrogen Substances 0.000 claims description 9
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical compound O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 claims description 9
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 9
- 238000001356 surgical procedure Methods 0.000 claims description 9
- 125000003118 aryl group Chemical group 0.000 claims description 8
- 230000000699 topical effect Effects 0.000 claims description 6
- 229910052736 halogen Inorganic materials 0.000 claims description 5
- 150000002367 halogens Chemical class 0.000 claims description 5
- 238000013532 laser treatment Methods 0.000 claims description 5
- VUWZPRWSIVNGKG-UHFFFAOYSA-N fluoromethane Chemical compound F[CH2] VUWZPRWSIVNGKG-UHFFFAOYSA-N 0.000 claims description 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 9
- 150000002431 hydrogen Chemical group 0.000 claims 6
- 210000002950 fibroblast Anatomy 0.000 description 41
- 108090000623 proteins and genes Proteins 0.000 description 37
- 102000008186 Collagen Human genes 0.000 description 26
- 108010035532 Collagen Proteins 0.000 description 26
- 230000014509 gene expression Effects 0.000 description 26
- 229920001436 collagen Polymers 0.000 description 25
- 230000015572 biosynthetic process Effects 0.000 description 21
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 18
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 18
- 210000002744 extracellular matrix Anatomy 0.000 description 18
- 229940125904 compound 1 Drugs 0.000 description 17
- 238000003786 synthesis reaction Methods 0.000 description 17
- 102000004169 proteins and genes Human genes 0.000 description 16
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 14
- 235000002639 sodium chloride Nutrition 0.000 description 13
- 208000027418 Wounds and injury Diseases 0.000 description 12
- 210000002808 connective tissue Anatomy 0.000 description 12
- 230000002500 effect on skin Effects 0.000 description 12
- 238000000034 method Methods 0.000 description 12
- 108010022452 Collagen Type I Proteins 0.000 description 11
- 102000012422 Collagen Type I Human genes 0.000 description 11
- 206010023330 Keloid scar Diseases 0.000 description 11
- -1 acetic Chemical class 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 230000015556 catabolic process Effects 0.000 description 9
- 238000006731 degradation reaction Methods 0.000 description 9
- 108020004999 messenger RNA Proteins 0.000 description 9
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 8
- 210000004027 cell Anatomy 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 230000001105 regulatory effect Effects 0.000 description 8
- 239000002562 thickening agent Substances 0.000 description 8
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 7
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 7
- AFYNADDZULBEJA-UHFFFAOYSA-N bicinchoninic acid Chemical compound C1=CC=CC2=NC(C=3C=C(C4=CC=CC=C4N=3)C(=O)O)=CC(C(O)=O)=C21 AFYNADDZULBEJA-UHFFFAOYSA-N 0.000 description 7
- 230000006378 damage Effects 0.000 description 7
- 238000011156 evaluation Methods 0.000 description 7
- 208000014674 injury Diseases 0.000 description 7
- 239000003755 preservative agent Substances 0.000 description 7
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 6
- 101001013150 Homo sapiens Interstitial collagenase Proteins 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 125000000217 alkyl group Chemical group 0.000 description 6
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 6
- 239000012894 fetal calf serum Substances 0.000 description 6
- 235000011187 glycerol Nutrition 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 238000003359 percent control normalization Methods 0.000 description 6
- 239000002953 phosphate buffered saline Substances 0.000 description 6
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 6
- 150000003214 pyranose derivatives Chemical class 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 230000000638 stimulation Effects 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 102100033601 Collagen alpha-1(I) chain Human genes 0.000 description 5
- 108020004635 Complementary DNA Proteins 0.000 description 5
- 101000990915 Homo sapiens Stromelysin-1 Proteins 0.000 description 5
- 238000011529 RT qPCR Methods 0.000 description 5
- 102100030416 Stromelysin-1 Human genes 0.000 description 5
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 5
- 206010052428 Wound Diseases 0.000 description 5
- 239000003963 antioxidant agent Substances 0.000 description 5
- 235000006708 antioxidants Nutrition 0.000 description 5
- 238000010804 cDNA synthesis Methods 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 239000002299 complementary DNA Substances 0.000 description 5
- 150000002243 furanoses Chemical class 0.000 description 5
- 230000035876 healing Effects 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 238000003762 quantitative reverse transcription PCR Methods 0.000 description 5
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- 102000007469 Actins Human genes 0.000 description 4
- 108010085238 Actins Proteins 0.000 description 4
- 108090001008 Avidin Proteins 0.000 description 4
- 102100031611 Collagen alpha-1(III) chain Human genes 0.000 description 4
- 102100028065 Fibulin-5 Human genes 0.000 description 4
- 101000993285 Homo sapiens Collagen alpha-1(III) chain Proteins 0.000 description 4
- 101000612134 Homo sapiens Procollagen C-endopeptidase enhancer 1 Proteins 0.000 description 4
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 4
- 102100041026 Procollagen C-endopeptidase enhancer 1 Human genes 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 108010029483 alpha 1 Chain Collagen Type I Proteins 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 229960002685 biotin Drugs 0.000 description 4
- 235000020958 biotin Nutrition 0.000 description 4
- 239000011616 biotin Substances 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 3
- 102100024337 Collagen alpha-1(VIII) chain Human genes 0.000 description 3
- 102100035784 Decorin Human genes 0.000 description 3
- 102100036411 Dermatopontin Human genes 0.000 description 3
- 102000016942 Elastin Human genes 0.000 description 3
- 108010014258 Elastin Proteins 0.000 description 3
- 102100033167 Elastin Human genes 0.000 description 3
- 108700039887 Essential Genes Proteins 0.000 description 3
- 101000909492 Homo sapiens Collagen alpha-1(VIII) chain Proteins 0.000 description 3
- 101001000206 Homo sapiens Decorin Proteins 0.000 description 3
- 101000851054 Homo sapiens Elastin Proteins 0.000 description 3
- 101001060252 Homo sapiens Fibulin-5 Proteins 0.000 description 3
- 102100031775 Leptin receptor Human genes 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 3
- 239000012911 assay medium Substances 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000002537 cosmetic Substances 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 229920002549 elastin Polymers 0.000 description 3
- 239000003974 emollient agent Substances 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 239000003906 humectant Substances 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 108010019813 leptin receptors Proteins 0.000 description 3
- 239000003605 opacifier Substances 0.000 description 3
- 230000003287 optical effect Effects 0.000 description 3
- 238000003752 polymerase chain reaction Methods 0.000 description 3
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 3
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 3
- 229960003415 propylparaben Drugs 0.000 description 3
- 238000003753 real-time PCR Methods 0.000 description 3
- 238000007634 remodeling Methods 0.000 description 3
- 238000010839 reverse transcription Methods 0.000 description 3
- 230000035882 stress Effects 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 238000011200 topical administration Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 230000029663 wound healing Effects 0.000 description 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- 208000002874 Acne Vulgaris Diseases 0.000 description 2
- 244000144927 Aloe barbadensis Species 0.000 description 2
- 235000002961 Aloe barbadensis Nutrition 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 description 2
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 2
- 102100031457 Collagen alpha-1(V) chain Human genes 0.000 description 2
- 229920000742 Cotton Polymers 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 238000008157 ELISA kit Methods 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 102000002068 Glycopeptides Human genes 0.000 description 2
- 108010015899 Glycopeptides Proteins 0.000 description 2
- 101000941708 Homo sapiens Collagen alpha-1(V) chain Proteins 0.000 description 2
- 101000929047 Homo sapiens Dermatopontin Proteins 0.000 description 2
- 101000687673 Homo sapiens Small integral membrane protein 6 Proteins 0.000 description 2
- 101000835083 Homo sapiens Tissue factor pathway inhibitor 2 Proteins 0.000 description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- 229930182816 L-glutamine Natural products 0.000 description 2
- 239000004166 Lanolin Substances 0.000 description 2
- 102000016267 Leptin Human genes 0.000 description 2
- 108010092277 Leptin Proteins 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 2
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 2
- 229930182555 Penicillin Natural products 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- DLRVVLDZNNYCBX-UHFFFAOYSA-N Polydextrose Polymers OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(O)O1 DLRVVLDZNNYCBX-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 102100026134 Tissue factor pathway inhibitor 2 Human genes 0.000 description 2
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 206010000496 acne Diseases 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 235000011399 aloe vera Nutrition 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 125000004429 atom Chemical group 0.000 description 2
- 229960000686 benzalkonium chloride Drugs 0.000 description 2
- UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 2
- 229960001950 benzethonium chloride Drugs 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 229940125782 compound 2 Drugs 0.000 description 2
- 229940126214 compound 3 Drugs 0.000 description 2
- 230000003436 cytoskeletal effect Effects 0.000 description 2
- 238000013523 data management Methods 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 229940088598 enzyme Drugs 0.000 description 2
- 238000000249 far-infrared magnetic resonance spectroscopy Methods 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 239000003205 fragrance Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 229940014259 gelatin Drugs 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 235000019388 lanolin Nutrition 0.000 description 2
- 229940039717 lanolin Drugs 0.000 description 2
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 2
- 229940039781 leptin Drugs 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 229960001855 mannitol Drugs 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 2
- 235000010981 methylcellulose Nutrition 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 229960002216 methylparaben Drugs 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 150000007530 organic bases Chemical class 0.000 description 2
- 229940049954 penicillin Drugs 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 210000002460 smooth muscle Anatomy 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000011477 surgical intervention Methods 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- HLZKNKRTKFSKGZ-UHFFFAOYSA-N tetradecan-1-ol Chemical compound CCCCCCCCCCCCCCO HLZKNKRTKFSKGZ-UHFFFAOYSA-N 0.000 description 2
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 2
- 229930003799 tocopherol Natural products 0.000 description 2
- 239000011732 tocopherol Substances 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- 235000010493 xanthan gum Nutrition 0.000 description 2
- 239000000230 xanthan gum Substances 0.000 description 2
- 229920001285 xanthan gum Polymers 0.000 description 2
- 229940082509 xanthan gum Drugs 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- HFVMEOPYDLEHBR-UHFFFAOYSA-N (2-fluorophenyl)-phenylmethanol Chemical compound C=1C=CC=C(F)C=1C(O)C1=CC=CC=C1 HFVMEOPYDLEHBR-UHFFFAOYSA-N 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- YONLFQNRGZXBBF-ZIAGYGMSSA-N (2r,3r)-2,3-dibenzoyloxybutanedioic acid Chemical compound O([C@@H](C(=O)O)[C@@H](OC(=O)C=1C=CC=CC=1)C(O)=O)C(=O)C1=CC=CC=C1 YONLFQNRGZXBBF-ZIAGYGMSSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- QTWJRLJHJPIABL-UHFFFAOYSA-N 2-methylphenol;3-methylphenol;4-methylphenol Chemical compound CC1=CC=C(O)C=C1.CC1=CC=CC(O)=C1.CC1=CC=CC=C1O QTWJRLJHJPIABL-UHFFFAOYSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 102100023679 40S ribosomal protein S28 Human genes 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 101150020966 Acta2 gene Proteins 0.000 description 1
- 235000019489 Almond oil Nutrition 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 1
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 108010022514 Collagen Type V Proteins 0.000 description 1
- 102000012432 Collagen Type V Human genes 0.000 description 1
- VMQMZMRVKUZKQL-UHFFFAOYSA-N Cu+ Chemical compound [Cu+] VMQMZMRVKUZKQL-UHFFFAOYSA-N 0.000 description 1
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 102000004237 Decorin Human genes 0.000 description 1
- 108090000738 Decorin Proteins 0.000 description 1
- 101710088341 Dermatopontin Proteins 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- RPWFJAMTCNSJKK-UHFFFAOYSA-N Dodecyl gallate Chemical compound CCCCCCCCCCCCOC(=O)C1=CC(O)=C(O)C(O)=C1 RPWFJAMTCNSJKK-UHFFFAOYSA-N 0.000 description 1
- 206010063560 Excessive granulation tissue Diseases 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 101710170766 Fibulin-5 Proteins 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000623076 Homo sapiens 40S ribosomal protein S28 Proteins 0.000 description 1
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 1
- 101000945357 Homo sapiens Collagen alpha-1(I) chain Proteins 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 229920000161 Locust bean gum Polymers 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 1
- 102000000422 Matrix Metalloproteinase 3 Human genes 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 235000019482 Palm oil Nutrition 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 229920001100 Polydextrose Polymers 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- CGNLCCVKSWNSDG-UHFFFAOYSA-N SYBR Green I Chemical compound CN(C)CCCN(CCC)C1=CC(C=C2N(C3=CC=CC=C3S2)C)=C2C=CC=CC2=[N+]1C1=CC=CC=C1 CGNLCCVKSWNSDG-UHFFFAOYSA-N 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical class OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric Acid Chemical compound [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 102000009618 Transforming Growth Factors Human genes 0.000 description 1
- 108010009583 Transforming Growth Factors Proteins 0.000 description 1
- 108010078814 Tumor Suppressor Protein p53 Proteins 0.000 description 1
- 239000004164 Wax ester Substances 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 229960004308 acetylcysteine Drugs 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229910001413 alkali metal ion Inorganic materials 0.000 description 1
- 229910001420 alkaline earth metal ion Inorganic materials 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 239000008168 almond oil Substances 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910021502 aluminium hydroxide Inorganic materials 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- REDXJYDRNCIFBQ-UHFFFAOYSA-N aluminium(3+) Chemical compound [Al+3] REDXJYDRNCIFBQ-UHFFFAOYSA-N 0.000 description 1
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
- 150000001413 amino acids Chemical group 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- 239000000305 astragalus gummifer gum Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960004365 benzoic acid Drugs 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 238000003236 bicinchoninic acid assay Methods 0.000 description 1
- 238000010876 biochemical test Methods 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 229940043253 butylated hydroxyanisole Drugs 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 1
- 229940067596 butylparaben Drugs 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000004203 carnauba wax Substances 0.000 description 1
- 235000013869 carnauba wax Nutrition 0.000 description 1
- 229940082483 carnauba wax Drugs 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 229960004106 citric acid Drugs 0.000 description 1
- 239000010634 clove oil Substances 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000012716 cod liver oil Nutrition 0.000 description 1
- 239000003026 cod liver oil Substances 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 239000012059 conventional drug carrier Substances 0.000 description 1
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 1
- 229910000366 copper(II) sulfate Inorganic materials 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 239000006184 cosolvent Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 229930003836 cresol Natural products 0.000 description 1
- 229940013361 cresol Drugs 0.000 description 1
- 238000002681 cryosurgery Methods 0.000 description 1
- WZHCOOQXZCIUNC-UHFFFAOYSA-N cyclandelate Chemical compound C1C(C)(C)CC(C)CC1OC(=O)C(O)C1=CC=CC=C1 WZHCOOQXZCIUNC-UHFFFAOYSA-N 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 229940099371 diacetylated monoglycerides Drugs 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 230000009274 differential gene expression Effects 0.000 description 1
- 229940008099 dimethicone Drugs 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- HRKQOINLCJTGBK-UHFFFAOYSA-L dioxidosulfate(2-) Chemical compound [O-]S[O-] HRKQOINLCJTGBK-UHFFFAOYSA-L 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- WBZKQQHYRPRKNJ-UHFFFAOYSA-L disulfite Chemical compound [O-]S(=O)S([O-])(=O)=O WBZKQQHYRPRKNJ-UHFFFAOYSA-L 0.000 description 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 1
- 235000010386 dodecyl gallate Nutrition 0.000 description 1
- 239000000555 dodecyl gallate Substances 0.000 description 1
- 229940080643 dodecyl gallate Drugs 0.000 description 1
- 229960001484 edetic acid Drugs 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 1
- 235000010228 ethyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004403 ethyl p-hydroxybenzoate Substances 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- 239000010642 eucalyptus oil Substances 0.000 description 1
- 229940044949 eucalyptus oil Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 150000002256 galaktoses Chemical class 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 229940075529 glyceryl stearate Drugs 0.000 description 1
- 210000001126 granulation tissue Anatomy 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 125000001183 hydrocarbyl group Chemical group 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 235000010420 locust bean gum Nutrition 0.000 description 1
- 239000000711 locust bean gum Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- PJUIMOJAAPLTRJ-UHFFFAOYSA-N monothioglycerol Chemical compound OCC(O)CS PJUIMOJAAPLTRJ-UHFFFAOYSA-N 0.000 description 1
- TXXHDPDFNKHHGW-UHFFFAOYSA-N muconic acid Chemical compound OC(=O)C=CC=CC(O)=O TXXHDPDFNKHHGW-UHFFFAOYSA-N 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 229940043348 myristyl alcohol Drugs 0.000 description 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-N naphthalene-2-sulfonic acid Chemical compound C1=CC=CC2=CC(S(=O)(=O)O)=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 235000010387 octyl gallate Nutrition 0.000 description 1
- 239000000574 octyl gallate Substances 0.000 description 1
- NRPKURNSADTHLJ-UHFFFAOYSA-N octyl gallate Chemical compound CCCCCCCCOC(=O)C1=CC(O)=C(O)C(O)=C1 NRPKURNSADTHLJ-UHFFFAOYSA-N 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 238000012261 overproduction Methods 0.000 description 1
- AICOOMRHRUFYCM-ZRRPKQBOSA-N oxazine, 1 Chemical compound C([C@@H]1[C@H](C(C[C@]2(C)[C@@H]([C@H](C)N(C)C)[C@H](O)C[C@]21C)=O)CC1=CC2)C[C@H]1[C@@]1(C)[C@H]2N=C(C(C)C)OC1 AICOOMRHRUFYCM-ZRRPKQBOSA-N 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 239000002540 palm oil Substances 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- RLZZZVKAURTHCP-UHFFFAOYSA-N phenanthrene-3,4-diol Chemical compound C1=CC=C2C3=C(O)C(O)=CC=C3C=CC2=C1 RLZZZVKAURTHCP-UHFFFAOYSA-N 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 235000013856 polydextrose Nutrition 0.000 description 1
- 239000001259 polydextrose Substances 0.000 description 1
- 229940035035 polydextrose Drugs 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000002861 polymer material Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229960003975 potassium Drugs 0.000 description 1
- 235000007686 potassium Nutrition 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 230000003334 potential effect Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 108010067415 progelatinase Proteins 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000008458 response to injury Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229920002477 rna polymer Polymers 0.000 description 1
- 235000019719 rose oil Nutrition 0.000 description 1
- 239000010666 rose oil Substances 0.000 description 1
- 239000008132 rose water Substances 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000036573 scar formation Effects 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 210000001626 skin fibroblast Anatomy 0.000 description 1
- 230000036560 skin regeneration Effects 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 230000037351 starvation Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229960004274 stearic acid Drugs 0.000 description 1
- 229940012831 stearyl alcohol Drugs 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 108091007196 stromelysin Proteins 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 150000005846 sugar alcohols Polymers 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- UWHCKJMYHZGTIT-UHFFFAOYSA-N tetraethylene glycol Chemical compound OCCOCCOCCOCCO UWHCKJMYHZGTIT-UHFFFAOYSA-N 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 102000055046 tissue-factor-pathway inhibitor 2 Human genes 0.000 description 1
- 108010016054 tissue-factor-pathway inhibitor 2 Proteins 0.000 description 1
- OGIDPMRJRNCKJF-UHFFFAOYSA-N titanium oxide Inorganic materials [Ti]=O OGIDPMRJRNCKJF-UHFFFAOYSA-N 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 125000002640 tocopherol group Chemical class 0.000 description 1
- 235000019149 tocopherols Nutrition 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 238000012384 transportation and delivery Methods 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 239000012178 vegetable wax Substances 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- 235000019386 wax ester Nutrition 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0827—Tripeptides containing heteroatoms different from O, S, or N
Abstract
The present invention relates to a compound of the following formula (I), as well as to a pharmaceutical composition comprising at least one compound of following formula (I) and at least one pharmaceutically acceptable excipient, for use in the treatment and/or prevention and/or attenuation of fibrosis diseases, in particular excessive scars such as keloids or hypertrophic scars.
Description
Glycopeptide derivatives for use in the treatment and/or prevention and/or attenuation of fibrosis diseases The present invention relates to glycopeptide derivatives, as well as pharmaceutical compositions containing such compounds, for use in the treatment and/or prevention and/or attenuation of fibrosis diseases and in particular for the treatment and/or prevention and/or attenuation of excessive scars such as keloids or hypertrophic scars.
During the classical wound healing process, three main complex steps are involved: 1) hemostasis/inflammation, 2) proliferation and 3) remodeling (BioMed Research International 2014, article ID747584). First, the aggregation of platelets and the delivery of cytokines stop the hemorrhage and prevent infection (formation of a fibrin clot). Then, the proliferation of fibroblasts, the angiogenesis and the synthesis of extracellular matrix lead to the regeneration of dermal and epidermal tissue.
And finally, the remodeling of the granulation tissue occurs.
Keloids and hypertrophic scars are the result of a dysfunction in the classical wound healing process following injury such as a surgical intervention, piercings, vaccination, acne, cuts, or burns. They consist of unaesthetic dense fibrous tissue that extends beyond the initial site of injury for the keloids or remain within the initial boundaries of injury for the hypertrophic scars.
Numerous treatments have been developed in order to treat, reduce and/or prevent keloids and hypertrophic scars such as conventional surgery, pressure therapy, topical silicone gel, radiation, laser, cryosurgery, injection of corticosteroids and chemical agents. Despite the large number of possible options to prevent and/or treat and/or attenuate keloids, none of them are really effective.
In this invention, an unexpected role of glycopeptide derivatives in the regulation of several genes involved in mechanism of reducing/treating/preventing fibrosis diseases such as keloids has been discovered.
During the classical wound healing process, three main complex steps are involved: 1) hemostasis/inflammation, 2) proliferation and 3) remodeling (BioMed Research International 2014, article ID747584). First, the aggregation of platelets and the delivery of cytokines stop the hemorrhage and prevent infection (formation of a fibrin clot). Then, the proliferation of fibroblasts, the angiogenesis and the synthesis of extracellular matrix lead to the regeneration of dermal and epidermal tissue.
And finally, the remodeling of the granulation tissue occurs.
Keloids and hypertrophic scars are the result of a dysfunction in the classical wound healing process following injury such as a surgical intervention, piercings, vaccination, acne, cuts, or burns. They consist of unaesthetic dense fibrous tissue that extends beyond the initial site of injury for the keloids or remain within the initial boundaries of injury for the hypertrophic scars.
Numerous treatments have been developed in order to treat, reduce and/or prevent keloids and hypertrophic scars such as conventional surgery, pressure therapy, topical silicone gel, radiation, laser, cryosurgery, injection of corticosteroids and chemical agents. Despite the large number of possible options to prevent and/or treat and/or attenuate keloids, none of them are really effective.
In this invention, an unexpected role of glycopeptide derivatives in the regulation of several genes involved in mechanism of reducing/treating/preventing fibrosis diseases such as keloids has been discovered.
2 This invention relates thus to a compound of the following formula I, Nr,OH
'n Ri R3 _ R2 (I) or a salt thereof, a solvate, a tautomer, a stereoisomer or a mixture of stereoisomers in any proportions, in particular a mixture of enantiomers, and particularly a racemate mixture, in which:
¨ n represents an integer from 1 to 6, ¨ m represents 0 or 1, ¨ p represents 0 or 1 ¨ R represents H, F, CH3, CH2F, or CH2OH, ¨ R1, R2 and R3 represent, independently from one another, H, F, or OH, - R4 represents a hydrogen, a halogen, or OH, - R6 and R7 represent, independently from each other, a hydrogen, a (Ci-C6)alkyl, an aryl, or an aryl-(Ci-C6)alkyl, for use in the treatment and/or prevention and/or attenuation of fibrosis diseases, in particular excessive scars such as keloids or hypertrophic scars.
The present invention relates also to the use of a compound of formula I as defined above, or a salt thereof, a solvate, a tautomer, a stereoisomer or a mixture of stereoisomers in any proportions, in particular a mixture of enantiomers, and particularly a racemate mixture, for the manufacture of a medicament intended for the treatment and/or prevention and/or attenuation of fibrosis diseases, in particular excessive scars such as keloids or hypertrophic scars.
The present invention relates also to the use of a compound of formula I as defined above, or a salt thereof, a solvate, a tautomer, a stereoisomer or a mixture of stereoisomers in any proportions, in particular a mixture of enantiomers, and
'n Ri R3 _ R2 (I) or a salt thereof, a solvate, a tautomer, a stereoisomer or a mixture of stereoisomers in any proportions, in particular a mixture of enantiomers, and particularly a racemate mixture, in which:
¨ n represents an integer from 1 to 6, ¨ m represents 0 or 1, ¨ p represents 0 or 1 ¨ R represents H, F, CH3, CH2F, or CH2OH, ¨ R1, R2 and R3 represent, independently from one another, H, F, or OH, - R4 represents a hydrogen, a halogen, or OH, - R6 and R7 represent, independently from each other, a hydrogen, a (Ci-C6)alkyl, an aryl, or an aryl-(Ci-C6)alkyl, for use in the treatment and/or prevention and/or attenuation of fibrosis diseases, in particular excessive scars such as keloids or hypertrophic scars.
The present invention relates also to the use of a compound of formula I as defined above, or a salt thereof, a solvate, a tautomer, a stereoisomer or a mixture of stereoisomers in any proportions, in particular a mixture of enantiomers, and particularly a racemate mixture, for the manufacture of a medicament intended for the treatment and/or prevention and/or attenuation of fibrosis diseases, in particular excessive scars such as keloids or hypertrophic scars.
The present invention relates also to the use of a compound of formula I as defined above, or a salt thereof, a solvate, a tautomer, a stereoisomer or a mixture of stereoisomers in any proportions, in particular a mixture of enantiomers, and
3 particularly a racemate mixture, in the treatment and/or prevention and/or attenuation of fibrosis diseases, in particular excessive scars such as keloids or hypertrophic scars.
The present invention relates also to a method of treating and/or preventing and/or attenuating fibrosis diseases, in particular excessive scars such as keloids or hypertrophic scars, comprising the administration to a person in need thereof of an effective amount of a compound of formula I as defined above, or a salt thereof, a solvate, a tautomer, a stereoisomer or a mixture of stereoisomers in any proportions, in particular a mixture of enantiomers, and particularly a racemate mixture.
Such compounds of formula I were described in international application W02015/140178, as well as their process of manufacture. These compounds are disclosed in this application for their use in the preservation and/or protection and/or regeneration of biological materials or microorganisms and for cosmetic applications such as anti-aging, skin protection or skin regeneration. In this application, it has been proven that the CF2 glycopeptides of formula I have a significant preservative/protective effect on human skin fibroblasts and human nasal epithelial cells in vitro under different stresses as in particular starvation conditions, UV
stress, oxidative stress or bacterial stress. There is no mention of potential application of these compounds for the treatment of fibrosis diseases as in particular hypertrophic scars and keloids. Moreover, such an application is not evident to a person skilled in the art.
The compounds according to the invention can be used in combination with, and more particular after, a laser or surgical treatment. Indeed, a patient suffering from a fibrosis disease, in particular excessive scars such as keloids or hypertrophic scars, can be first treated with laser or by surgery to eliminate the excess fibrous connective tissue and then a compound according to the invention can be applied topically on the wound during its healing in order to prevent the reappearance of the excess fibrous connective tissue.
In the context of the present invention, a salt can be:
(1) an acid addition salt formed with an inorganic acid such as hydrochloric, hydrobromic, sulfuric, nitric and phosphoric acid and the like; or formed with an
The present invention relates also to a method of treating and/or preventing and/or attenuating fibrosis diseases, in particular excessive scars such as keloids or hypertrophic scars, comprising the administration to a person in need thereof of an effective amount of a compound of formula I as defined above, or a salt thereof, a solvate, a tautomer, a stereoisomer or a mixture of stereoisomers in any proportions, in particular a mixture of enantiomers, and particularly a racemate mixture.
Such compounds of formula I were described in international application W02015/140178, as well as their process of manufacture. These compounds are disclosed in this application for their use in the preservation and/or protection and/or regeneration of biological materials or microorganisms and for cosmetic applications such as anti-aging, skin protection or skin regeneration. In this application, it has been proven that the CF2 glycopeptides of formula I have a significant preservative/protective effect on human skin fibroblasts and human nasal epithelial cells in vitro under different stresses as in particular starvation conditions, UV
stress, oxidative stress or bacterial stress. There is no mention of potential application of these compounds for the treatment of fibrosis diseases as in particular hypertrophic scars and keloids. Moreover, such an application is not evident to a person skilled in the art.
The compounds according to the invention can be used in combination with, and more particular after, a laser or surgical treatment. Indeed, a patient suffering from a fibrosis disease, in particular excessive scars such as keloids or hypertrophic scars, can be first treated with laser or by surgery to eliminate the excess fibrous connective tissue and then a compound according to the invention can be applied topically on the wound during its healing in order to prevent the reappearance of the excess fibrous connective tissue.
In the context of the present invention, a salt can be:
(1) an acid addition salt formed with an inorganic acid such as hydrochloric, hydrobromic, sulfuric, nitric and phosphoric acid and the like; or formed with an
4 organic acid such as acetic, benzenesulfonic, fumaric, glucoheptonic, gluconic, glutamic, glycolic, hydroxynaphtoic, 2-hydroxyethanesulfonic, lactic, maleic, malic, mandelic, methanesulfonic, muconic, 2-naphtalenesulfonic, propionic, succinic, dibenzoyl-L-tartaric, tartaric, p-toluenesulfonic, trimethylacetic and trifluoroacetic acid and the like, or (2) a salt formed when an acid proton present in the compound is either replaced by a metal ion, such as an alkali metal ion, an alkaline-earth metal ion, or an aluminium ion; or coordinated with an organic or inorganic base. Acceptable organic bases comprise diethanolamine, ethanolamine, N-methylglucamine, triethanolamine, tromethamine and the like. Acceptable inorganic bases comprise aluminium hydroxide, calcium hydroxide, potassium hydroxide, sodium carbonate, sodium hydroxide and the like.
In the context of the present invention, solvates of the compounds of the present invention include conventional solvates such as those formed during the last step of the preparation of the compounds of the invention due to the presence of solvents.
As an example, mention may be made of solvates due to the presence of water (these solvates are also called hydrates) or ethanol.
For the purpose of this invention, "tautomer" is intended to designate the various tautomer forms that the sugar of compound of formula (I) may assume, namely a pyranose (6-membered ring), furanose (5-membered ring) or linear (open form) form.
However, for practical reasons, the sugar of compound of formula (I) is represented in the present description by its pyranose form.
However, the compounds of the invention can assume various tautomer forms only when the radical R4 represents an OH group, R1 having also to represent an OH
group in order that the compounds of the invention can be in the furanose form.
Thus, for example, in the galactose series, the compounds of the invention might appear under the following various forms:
H
H 1 H-43\ CFX-A HO
HO H OH N.----1 OH
HOo 13-CF
1-101"-----CFX-A
, HO bH
H /
I-1_0. HO
H'',,i , HO \ OH Linear HO N.----1 CFX-A
H CFX-A u-CF
a-CF
Furanoses Pyranoses R CN .,)1 Ri R3 "n The group R2 when R4 = Ri = OH can thus assume the following tautomer forms:
HO F2 H k R,k,C1\11õH
"n HO, R3
In the context of the present invention, solvates of the compounds of the present invention include conventional solvates such as those formed during the last step of the preparation of the compounds of the invention due to the presence of solvents.
As an example, mention may be made of solvates due to the presence of water (these solvates are also called hydrates) or ethanol.
For the purpose of this invention, "tautomer" is intended to designate the various tautomer forms that the sugar of compound of formula (I) may assume, namely a pyranose (6-membered ring), furanose (5-membered ring) or linear (open form) form.
However, for practical reasons, the sugar of compound of formula (I) is represented in the present description by its pyranose form.
However, the compounds of the invention can assume various tautomer forms only when the radical R4 represents an OH group, R1 having also to represent an OH
group in order that the compounds of the invention can be in the furanose form.
Thus, for example, in the galactose series, the compounds of the invention might appear under the following various forms:
H
H 1 H-43\ CFX-A HO
HO H OH N.----1 OH
HOo 13-CF
1-101"-----CFX-A
, HO bH
H /
I-1_0. HO
H'',,i , HO \ OH Linear HO N.----1 CFX-A
H CFX-A u-CF
a-CF
Furanoses Pyranoses R CN .,)1 Ri R3 "n The group R2 when R4 = Ri = OH can thus assume the following tautomer forms:
HO F2 H k R,k,C1\11õH
"n HO, R3
5 ¨ pyranose form: R2 , N<)i R "n ¨ furanose form: R2 R3 , and OH F2 H k CN.,11 R
"n ¨ linear form: R2
"n ¨ linear form: R2
6 R.::yCN
µ in Ri R3 In the same way, the group R2 when R4 = Ri = OH can thus assume the following tautomer forms:
R.:CN.,),1 "n ,,õ
¨ pyranose form: R2 , R "n ¨ furanose form: R2 R3 , and nu 0 F2 H
R
.......sj,c -.'- i,.....õ..A..url n õR3 HO
¨ linear form: R2 .
The anomeric carbon can appear in two different configurations in the closed pyranose and furanose forms.
The compounds of the invention can assume different tautomer forms which can be present in solution in equilibrium, with optionally a major tautomer form relatively to the other(s) tautomer form(s), or the compounds of the invention can assume only one tautomer form, such as only a pyranose form. This will depend notably on the nature of the medium, the temperature, the concentration of the compound, etc.
In this last case where the sugar assumes only one tautomer form, it is possible to block the configuration of the sugar in this tautomeric form when R4 = OH
is transformed, notably by substitution of the OH group or conversion in a hydrogen or halogen atom.
Within the meaning of this invention, "stereoisomers" is intended to designate diastereoisomers or enantiomers. These are therefore optical isomers.
Stereoisomers which are not mirror images of one another are thus designated as "diastereoisomers,"
µ in Ri R3 In the same way, the group R2 when R4 = Ri = OH can thus assume the following tautomer forms:
R.:CN.,),1 "n ,,õ
¨ pyranose form: R2 , R "n ¨ furanose form: R2 R3 , and nu 0 F2 H
R
.......sj,c -.'- i,.....õ..A..url n õR3 HO
¨ linear form: R2 .
The anomeric carbon can appear in two different configurations in the closed pyranose and furanose forms.
The compounds of the invention can assume different tautomer forms which can be present in solution in equilibrium, with optionally a major tautomer form relatively to the other(s) tautomer form(s), or the compounds of the invention can assume only one tautomer form, such as only a pyranose form. This will depend notably on the nature of the medium, the temperature, the concentration of the compound, etc.
In this last case where the sugar assumes only one tautomer form, it is possible to block the configuration of the sugar in this tautomeric form when R4 = OH
is transformed, notably by substitution of the OH group or conversion in a hydrogen or halogen atom.
Within the meaning of this invention, "stereoisomers" is intended to designate diastereoisomers or enantiomers. These are therefore optical isomers.
Stereoisomers which are not mirror images of one another are thus designated as "diastereoisomers,"
7 and stereoisomers which are non-superimposable mirror images are designated as "enantiomers".
Notably, the sugar moiety and the amino acid moieties of the compounds of the invention can belong to the D or L series.
A carbon atom bond to four non-identical substituents is called a "chiral centre".
An equimolar mixture of two enantiomers is called a racemate mixture.
The term "halogen" as used in the present invention refers to an atom of fluorine, bromine, chlorine or iodine. Advantageously, this is an atom of fluorine.
The term "(Ci-C6)-alkyl" as used in the present invention refers to a saturated, linear or branched hydrocarbon chain comprising from 1 to 6 carbon atoms, in particular the methyl, ethyl, n-propyl, isopropyl, n-butyl, iso-butyl, sec-butyl, tert-butyl, n-pentyl, n-hexyl groups. It can be in particular a methyl group.
The term "aryl", as used in the present invention, refers to an aromatic hydrocarbon group comprising preferably 6 to 10 carbon atoms and comprising one or more fused rings, such as, for example, a phenyl or naphtyl group.
Advantageously, it will be a phenyl group.
The term "aryl-(Ci-C6)-alkyl" as used in the present invention refers to any aryl group as defined above, which is bound to the molecule by means of a (Ci-C6)-alkyl group as defined above. In particular, it can be a benzyl group.
By "fibrosis disease" is meant in the present invention a disease involving the formation of excess fibrous connective tissue. When this formation of excess fibrous connective tissue occurs in response to injury (for ex. a surgical intervention, piercings, vaccination, acne, cuts, or burns), the fibrosis disease is called "excessive scar". It can be keloids or hypertrophic scars. They consist of unaesthetic dense fibrous tissue that extends beyond the initial site of injury for the keloids or remain within the initial boundaries of injury for the hypertrophic scars.
By "treatment" of a disease is meant in the present invention the disappearance of the symptom(s) of the disease, i.e. the excess fibrous connective tissue in the case of a fibrosis disease.
By "prevention" of a disease is meant in the present invention the fact to prevent or reduce the appearance of the symptom(s) of the disease, i.e. the excess fibrous connective tissue in the case of a fibrosis disease.
Notably, the sugar moiety and the amino acid moieties of the compounds of the invention can belong to the D or L series.
A carbon atom bond to four non-identical substituents is called a "chiral centre".
An equimolar mixture of two enantiomers is called a racemate mixture.
The term "halogen" as used in the present invention refers to an atom of fluorine, bromine, chlorine or iodine. Advantageously, this is an atom of fluorine.
The term "(Ci-C6)-alkyl" as used in the present invention refers to a saturated, linear or branched hydrocarbon chain comprising from 1 to 6 carbon atoms, in particular the methyl, ethyl, n-propyl, isopropyl, n-butyl, iso-butyl, sec-butyl, tert-butyl, n-pentyl, n-hexyl groups. It can be in particular a methyl group.
The term "aryl", as used in the present invention, refers to an aromatic hydrocarbon group comprising preferably 6 to 10 carbon atoms and comprising one or more fused rings, such as, for example, a phenyl or naphtyl group.
Advantageously, it will be a phenyl group.
The term "aryl-(Ci-C6)-alkyl" as used in the present invention refers to any aryl group as defined above, which is bound to the molecule by means of a (Ci-C6)-alkyl group as defined above. In particular, it can be a benzyl group.
By "fibrosis disease" is meant in the present invention a disease involving the formation of excess fibrous connective tissue. When this formation of excess fibrous connective tissue occurs in response to injury (for ex. a surgical intervention, piercings, vaccination, acne, cuts, or burns), the fibrosis disease is called "excessive scar". It can be keloids or hypertrophic scars. They consist of unaesthetic dense fibrous tissue that extends beyond the initial site of injury for the keloids or remain within the initial boundaries of injury for the hypertrophic scars.
By "treatment" of a disease is meant in the present invention the disappearance of the symptom(s) of the disease, i.e. the excess fibrous connective tissue in the case of a fibrosis disease.
By "prevention" of a disease is meant in the present invention the fact to prevent or reduce the appearance of the symptom(s) of the disease, i.e. the excess fibrous connective tissue in the case of a fibrosis disease.
8 By "attenuation" of a disease is meant in the present invention the modulation, in particular the reduction of the symptom(s) of the disease, i.e. the excess fibrous connective tissue in the case of a fibrosis disease. It can be for example the reduction of the amount excess fibrous connective tissue. Thus, the size of a keloid or hypertrophic scar can be reduced.
According to a particular embodiment, the compounds of formula I of the present invention have one of the following formulas (Ia), (Ib), (Ic):
IR:,,,,N.H.rNAN.r0H
n H
Ri R3 R2 (Ia) t,C
OH
Ri R3 R2 (Ib) n Ri R3 R2 (Ic) in which n, R, R1, R25 R35 R45 R6 and R7 are as defined above or below.
According to a particular embodiment, n represents an integer from 2 to 6, notably from 3 to 5, such as 4.
R can represent more particularly a CH2OH group.
R15 R2 and R3 can each represent a OH group.
According to a particular embodiment, R represents a CH2OH group and R15 R2 and R3 each represent a OH group.
R4 can represent more particularly a OH group.
According to a particular embodiment, the compounds of formula I of the present invention have one of the following formulas (Ia), (Ib), (Ic):
IR:,,,,N.H.rNAN.r0H
n H
Ri R3 R2 (Ia) t,C
OH
Ri R3 R2 (Ib) n Ri R3 R2 (Ic) in which n, R, R1, R25 R35 R45 R6 and R7 are as defined above or below.
According to a particular embodiment, n represents an integer from 2 to 6, notably from 3 to 5, such as 4.
R can represent more particularly a CH2OH group.
R15 R2 and R3 can each represent a OH group.
According to a particular embodiment, R represents a CH2OH group and R15 R2 and R3 each represent a OH group.
R4 can represent more particularly a OH group.
9 According to a particular embodiment, R represents a CH2OH group and R1, R25 R3 and R4 each represent a OH group.
R6 and R7 can represent, independently from each other, a (Ci-C6)alkyl, an aryl or an aryl-(Ci-C6)alkyl; more particularly a (Ci-C6)alkyl such as a methyl.
According to a particular embodiment, R represents a CH2OH group; R1, R2, R3 and R4 each represent a OH group; and R6 and R7 represent, independently from each other, a (Ci-C6)alkyl such as a methyl.
The compound of the present invention can be chosen among the following compounds:
HO NN N
NH2 0 z OH Compound 1, HQ F2 H ll NH2 0 =-HU' y '''OH
OH Compound 2, HO
OH Compound 3, HOCD<,=.CN
OH
HOlv-Y.'10H NH2 OH Compound 4, and salts and/or solvates thereof.
The present invention relates also to a pharmaceutical composition comprising at least one compound of formula I as defined above, according to any of the disclosed embodiments, or a salt thereof, a solvate, a tautomer, a stereoisomer or a mixture of stereoisomers in any proportions, in particular a mixture of enantiomers, and particularly a racemate mixture, and at least one pharmaceutically acceptable excipient, for use in the treatment and/or prevention and/or attenuation of fibrosis diseases, in particular excessive scars such as keloids or hypertrophic scars.
The present invention relates also to the use of said pharmaceutical composition 5 for the manufacture of a medicament intended for the treatment and/or prevention and/or attenuation of fibrosis diseases, in particular excessive scars such as keloids or hypertrophic scars.
The present invention relates also to the use of said pharmaceutical composition in the treatment and/or prevention and/or attenuation of fibrosis diseases, in particular
R6 and R7 can represent, independently from each other, a (Ci-C6)alkyl, an aryl or an aryl-(Ci-C6)alkyl; more particularly a (Ci-C6)alkyl such as a methyl.
According to a particular embodiment, R represents a CH2OH group; R1, R2, R3 and R4 each represent a OH group; and R6 and R7 represent, independently from each other, a (Ci-C6)alkyl such as a methyl.
The compound of the present invention can be chosen among the following compounds:
HO NN N
NH2 0 z OH Compound 1, HQ F2 H ll NH2 0 =-HU' y '''OH
OH Compound 2, HO
OH Compound 3, HOCD<,=.CN
OH
HOlv-Y.'10H NH2 OH Compound 4, and salts and/or solvates thereof.
The present invention relates also to a pharmaceutical composition comprising at least one compound of formula I as defined above, according to any of the disclosed embodiments, or a salt thereof, a solvate, a tautomer, a stereoisomer or a mixture of stereoisomers in any proportions, in particular a mixture of enantiomers, and particularly a racemate mixture, and at least one pharmaceutically acceptable excipient, for use in the treatment and/or prevention and/or attenuation of fibrosis diseases, in particular excessive scars such as keloids or hypertrophic scars.
The present invention relates also to the use of said pharmaceutical composition 5 for the manufacture of a medicament intended for the treatment and/or prevention and/or attenuation of fibrosis diseases, in particular excessive scars such as keloids or hypertrophic scars.
The present invention relates also to the use of said pharmaceutical composition in the treatment and/or prevention and/or attenuation of fibrosis diseases, in particular
10 excessive scars such as keloids or hypertrophic scars.
The present invention relates also to a method of treating and/or preventing and/or attenuating fibrosis diseases, in particular excessive scars such as keloids or hypertrophic scars, comprising the administration to a person in need thereof of an effective amount of said pharmaceutical composition.
The pharmaceutical compositions of the invention are more particularly intended to topical (e.g. transdermal) administration or parenteral (e.g. subcutaneous) administration, preferably topical administration.
For the purpose of the invention, the term "pharmaceutically acceptable" is intended to mean what is useful to the preparation of a pharmaceutical composition, and what is generally safe and non toxic, for a pharmaceutical use.
By "pharmaceutical composition" is meant in the framework of the present invention a composition having preventive and curative properties towards diseases, and more particularly fibrosis diseases as defined above. In the framework of the present invention, it can be a cosmeceutical (i.e. a composition having both cosmetic and pharmaceutical properties) or dermatological composition.
By "topical" administration is meant in the framework of the present invention an administration on the skin or on mucous membranes (e.g. conjunctiva).
The compounds of the invention can be used in a pharmaceutical composition at a dose ranging from 0.01 mg to 1000 mg a day, administered in only one dose once a
The present invention relates also to a method of treating and/or preventing and/or attenuating fibrosis diseases, in particular excessive scars such as keloids or hypertrophic scars, comprising the administration to a person in need thereof of an effective amount of said pharmaceutical composition.
The pharmaceutical compositions of the invention are more particularly intended to topical (e.g. transdermal) administration or parenteral (e.g. subcutaneous) administration, preferably topical administration.
For the purpose of the invention, the term "pharmaceutically acceptable" is intended to mean what is useful to the preparation of a pharmaceutical composition, and what is generally safe and non toxic, for a pharmaceutical use.
By "pharmaceutical composition" is meant in the framework of the present invention a composition having preventive and curative properties towards diseases, and more particularly fibrosis diseases as defined above. In the framework of the present invention, it can be a cosmeceutical (i.e. a composition having both cosmetic and pharmaceutical properties) or dermatological composition.
By "topical" administration is meant in the framework of the present invention an administration on the skin or on mucous membranes (e.g. conjunctiva).
The compounds of the invention can be used in a pharmaceutical composition at a dose ranging from 0.01 mg to 1000 mg a day, administered in only one dose once a
11 day or in several doses along the day, for example twice a day in equal doses.
The daily administered dose is advantageously comprises between 5 mg and 500 mg, and more advantageously between 10 mg and 200 mg. However, it can be necessary to use doses out of these ranges, which could be noticed by the person skilled in the art.
For parenteral, in particular subcutaneous, administration, the pharmaceutical composition according to the invention can be in the form of an aqueous suspension or solution which is advantageously sterile.
Such parenteral (e.g. subcutaneous) compositions will contain advantageously a physiologically acceptable medium, generally based on an isotonic saline solution, i.e.
0.9% NaCl aqueous solution (normal saline). Non-aqueous water miscible co-solvent, such as ethanol, glycerin, propylene glycol or n¨lactamide, can also be used.
The parenteral composition of the invention can also comprise one or more additive(s), such as suspending agents, wetting agents, preservatives, antioxidants, chelating agents, buffering agents, tonicity adjusting agents, etc. Such additives are conventional to those of skill in the art.
Suspending agents can be an alginate, sodium carboxymethyl cellulose, methyl cellulose, hydroxyl methyl cellulose, hydroxyl ethyl cellulose, hydroxylpropyl methyl cellulose, microcrystalline cellulose,a gum such as acacia, tragacanth or xanthan gum, gelatin, a carrageenan, polyvinyl pyrrolidone, etc.
Wetting agents can be glycerin, propylene glycol or also nonionic surfactants such as a lecithin, a polysorbate or a poloxamer.
Preservatives can be benzyl alcohol, phenol, cresol, chlorobutanol, a paraben such as methylparaben, propylparaben or propylparaben, benzalkonium chloride, benzethonium chloride, etc.
Antioxidants can be ascorbic acid, citric acid, acetylcysteine, sulfurous acid salts (bisulfite, metabisulfite), monothioglycerol, sodium formalhedyde sulfoxylate, thiourea, tocopherol, etc.
Chelating agents can be an ethylene diamine tetraacetic acid (EDTA) salt.
Buffering agents can be acetate, citrate, tartrate, phosphate, triethanolamine (TR1S), etc.
Tonicity adjusting agents can be dextrose, glycerol, sodium chloride, glycerin, mannitol, etc.
The daily administered dose is advantageously comprises between 5 mg and 500 mg, and more advantageously between 10 mg and 200 mg. However, it can be necessary to use doses out of these ranges, which could be noticed by the person skilled in the art.
For parenteral, in particular subcutaneous, administration, the pharmaceutical composition according to the invention can be in the form of an aqueous suspension or solution which is advantageously sterile.
Such parenteral (e.g. subcutaneous) compositions will contain advantageously a physiologically acceptable medium, generally based on an isotonic saline solution, i.e.
0.9% NaCl aqueous solution (normal saline). Non-aqueous water miscible co-solvent, such as ethanol, glycerin, propylene glycol or n¨lactamide, can also be used.
The parenteral composition of the invention can also comprise one or more additive(s), such as suspending agents, wetting agents, preservatives, antioxidants, chelating agents, buffering agents, tonicity adjusting agents, etc. Such additives are conventional to those of skill in the art.
Suspending agents can be an alginate, sodium carboxymethyl cellulose, methyl cellulose, hydroxyl methyl cellulose, hydroxyl ethyl cellulose, hydroxylpropyl methyl cellulose, microcrystalline cellulose,a gum such as acacia, tragacanth or xanthan gum, gelatin, a carrageenan, polyvinyl pyrrolidone, etc.
Wetting agents can be glycerin, propylene glycol or also nonionic surfactants such as a lecithin, a polysorbate or a poloxamer.
Preservatives can be benzyl alcohol, phenol, cresol, chlorobutanol, a paraben such as methylparaben, propylparaben or propylparaben, benzalkonium chloride, benzethonium chloride, etc.
Antioxidants can be ascorbic acid, citric acid, acetylcysteine, sulfurous acid salts (bisulfite, metabisulfite), monothioglycerol, sodium formalhedyde sulfoxylate, thiourea, tocopherol, etc.
Chelating agents can be an ethylene diamine tetraacetic acid (EDTA) salt.
Buffering agents can be acetate, citrate, tartrate, phosphate, triethanolamine (TR1S), etc.
Tonicity adjusting agents can be dextrose, glycerol, sodium chloride, glycerin, mannitol, etc.
12 For topical administration, the pharmaceutical composition according to the invention can be in the usual forms for a topical administration including creams, lotions, serums, gels, foams, dispersions, suspensions, emulsions, sprays, shampoos, masks, body milks, etc. The active ingredient can be administered in unit forms for administration, mixed with conventional pharmaceutical carriers, to animals, preferably mammals including humans.
Such topical compositions generally contain a physiologically acceptable medium, notably based on water or a solvent such as alcohols (for ex.
ethanol), ethers or glyco ls.
The topical composition of the invention can also comprise one or more additive(s), such as antioxidants, emollients, humectants, thickening agents, fragrances, preservatives, pigments or colorants, or opacifiers. Such additives are conventional to those of skill in the art.
Antioxidants can be used to protect ingredients of the composition from oxidizing agents that are included within or come in contact with the composition.
Examples of antioxidants include ascorbyl palmitate, butylated hydroxyanisole, butylated hydroxytoluene, potassium propyl gallate, octyl gallate, dodecyl gallate, phenyl-a-napthyl-amine, and tocopherols such as a-tocopherol.
Emollients are agents that soften and smooth the skin. Examples of emollients include oils and waxes such as siloxanes such as dimethicone and derivatives thereof, microcrystaline wax, polyethylene, triglyceride esters such as those of castor oil, cocoa butter, safflower oil, corn oil, olive oil, cod liver oil, almond oil, palm oil, squalene, and soybean oil, acetylated monoglycerides, ethoxylated glycerides, fatty acids, alkyl esters of fatty acids, alkenyl esters of fatty acids, fatty alcohols, fatty alcohol ethers, ether-esters, lanolin and derivatives of lanolin, polyhydric alcohol esters, wax esters such as beeswax, vegetable waxes, phospholids, sterols, isopropyl palmitate or glyceryl stearate.
Humectants are used to increase and maintain moisture in the skin. Examples of humectants include propylene glycol, butylene glycol, polyethylene glycol (PEG) (such as PEG-4 to PEG-32), glycerol (also called glycerin), sorbitol, xylitol, maltitol, mannitol, polydextrose, hyaluronic acid and its salts (such as sodium or potassium salt), urea, aloe vera, honey, etc.
Such topical compositions generally contain a physiologically acceptable medium, notably based on water or a solvent such as alcohols (for ex.
ethanol), ethers or glyco ls.
The topical composition of the invention can also comprise one or more additive(s), such as antioxidants, emollients, humectants, thickening agents, fragrances, preservatives, pigments or colorants, or opacifiers. Such additives are conventional to those of skill in the art.
Antioxidants can be used to protect ingredients of the composition from oxidizing agents that are included within or come in contact with the composition.
Examples of antioxidants include ascorbyl palmitate, butylated hydroxyanisole, butylated hydroxytoluene, potassium propyl gallate, octyl gallate, dodecyl gallate, phenyl-a-napthyl-amine, and tocopherols such as a-tocopherol.
Emollients are agents that soften and smooth the skin. Examples of emollients include oils and waxes such as siloxanes such as dimethicone and derivatives thereof, microcrystaline wax, polyethylene, triglyceride esters such as those of castor oil, cocoa butter, safflower oil, corn oil, olive oil, cod liver oil, almond oil, palm oil, squalene, and soybean oil, acetylated monoglycerides, ethoxylated glycerides, fatty acids, alkyl esters of fatty acids, alkenyl esters of fatty acids, fatty alcohols, fatty alcohol ethers, ether-esters, lanolin and derivatives of lanolin, polyhydric alcohol esters, wax esters such as beeswax, vegetable waxes, phospholids, sterols, isopropyl palmitate or glyceryl stearate.
Humectants are used to increase and maintain moisture in the skin. Examples of humectants include propylene glycol, butylene glycol, polyethylene glycol (PEG) (such as PEG-4 to PEG-32), glycerol (also called glycerin), sorbitol, xylitol, maltitol, mannitol, polydextrose, hyaluronic acid and its salts (such as sodium or potassium salt), urea, aloe vera, honey, etc.
13 Thickening agents are used to increase the viscosity and thickness of the composition. Examples of thickening agents include lipid thickening agents such as Cetyl Alcohol, Stearyl Alcohol, Myristyl Alcohol, Carnauba Wax, or Stearic acid;
naturally derived thickening agents such as Cellulose derivatives like Hydroxyethylcellulose, Guar gum, Locust Bean Gum, Xanthan Gum, or Gelatin;
mineral thickening agents such as Silica, Bentonite, or Magnesium Aluminum Silicate;
synthetic thickening agents such as Carbomer; ionic thickening agents such as NaCl.
Examples of fragrances or perfume include peppermint, rose oil, rose water, aloe vera, clove oil, menthol, camphor, eucalyptus oil, and other plant extracts.
To eliminate certain odours from compositions, masking agents may be used.
Preservatives can be used to protect the composition from degradation.
Examples of preservatives include phenoxyethanol, butylparaben, ethylparaben, methylparaben, propylparaben, benzalkonium chloride, benzethonium chloride, benzoic acid, benzyl alcohol, and mixtures thereof such as liquipar oil. However, the composition of the present invention can be preservative free.
Pigments or colorants are used to modify the color of the composition, such as to obtain a white composition.
Opacifiers, such as titanium oxide, are used in clear or transparent composition in order to render it opaque. The present invention can thus be clear or opaque according to the use or not of an opacifier.
The pharmaceutical composition according to the invention can be used in combination with, and more particular after, a laser or surgical treatment.
Indeed, a patient suffering from a fibrosis disease, in particular excessive scars such as keloids or hypertrophic scars, can be first treated with laser or by surgery to eliminate the excess fibrous connective tissue and then a pharmaceutical composition according to the invention can be applied topically on the wound during its healing in order to prevent the reappearance of the excess fibrous connective tissue.
The present invention concerns also a dressing comprising a pad, compress or sponge impregnated with a pharmaceutical composition according to the present invention as defined above comprising at least one compound of formula I as defined
naturally derived thickening agents such as Cellulose derivatives like Hydroxyethylcellulose, Guar gum, Locust Bean Gum, Xanthan Gum, or Gelatin;
mineral thickening agents such as Silica, Bentonite, or Magnesium Aluminum Silicate;
synthetic thickening agents such as Carbomer; ionic thickening agents such as NaCl.
Examples of fragrances or perfume include peppermint, rose oil, rose water, aloe vera, clove oil, menthol, camphor, eucalyptus oil, and other plant extracts.
To eliminate certain odours from compositions, masking agents may be used.
Preservatives can be used to protect the composition from degradation.
Examples of preservatives include phenoxyethanol, butylparaben, ethylparaben, methylparaben, propylparaben, benzalkonium chloride, benzethonium chloride, benzoic acid, benzyl alcohol, and mixtures thereof such as liquipar oil. However, the composition of the present invention can be preservative free.
Pigments or colorants are used to modify the color of the composition, such as to obtain a white composition.
Opacifiers, such as titanium oxide, are used in clear or transparent composition in order to render it opaque. The present invention can thus be clear or opaque according to the use or not of an opacifier.
The pharmaceutical composition according to the invention can be used in combination with, and more particular after, a laser or surgical treatment.
Indeed, a patient suffering from a fibrosis disease, in particular excessive scars such as keloids or hypertrophic scars, can be first treated with laser or by surgery to eliminate the excess fibrous connective tissue and then a pharmaceutical composition according to the invention can be applied topically on the wound during its healing in order to prevent the reappearance of the excess fibrous connective tissue.
The present invention concerns also a dressing comprising a pad, compress or sponge impregnated with a pharmaceutical composition according to the present invention as defined above comprising at least one compound of formula I as defined
14 previously, according to any of the disclosed embodiments, or a salt thereof, a solvate, a tautomer, a stereoisomer or a mixture of stereoisomers in any proportions, in particular a mixture of enantiomers, and particularly a racemate mixture, and at least one pharmaceutically acceptable excipient.
Such a dressing can be applied to an injury / a wound during the healing step in order to prevent or reduce the appearance of keloids or hypertrophic scars.
Thus it can be for use in the treatment and/or prevention and/or attenuation, notably in the prevention, of fibrosis diseases, in particular excessive scars such as keloids or hypertrophic scars.
It is thus preferably sterile.
Such a dressing can be more particularly a pressure dressing.
The pad, compress or sponge can be made of various materials, preferably absorbent materials, such as cotton, gauze, a porous polymer material, or a combination thereof, notably cotton and/or gauze.
It can also comprise a bandage or adhesive means in order to maintain the pad or compress in close contact with the injury or wound.
The present invention relates also to a dressing as defined above for use in the treatment and/or prevention and/or attenuation of fibrosis diseases, in particular excessive scars such as keloids or hypertrophic scars.
The present invention relates also to the use of a dressing as defined above for the manufacture of a medicament intended for the treatment and/or prevention and/or attenuation of fibrosis diseases, in particular excessive scars such as keloids or hypertrophic scars.
The present invention relates also to the use of as defined above in the treatment and/or prevention and/or attenuation of fibrosis diseases, in particular excessive scars such as keloids or hypertrophic scars.
The present invention relates also to a method of treating and/or preventing and/or attenuating fibrosis diseases, in particular excessive scars such as keloids or hypertrophic scars, comprising the application to a person in need thereof of a dressing as defined above.
This dressing can be used in combination with, and more particular after, a laser or surgical treatment. Indeed, a patient suffering from a fibrosis disease, in particular excessive scars such as keloids or hypertrophic scars, can be first treated with laser or by surgery to eliminate the excess fibrous connective tissue and then a dressing 5 according to the invention can be applied on the wound during its healing in order to prevent the reappearance of the excess fibrous connective tissue.
The present invention is illustrated by the following non-limitative examples.
The following abbreviations have been used in the examples:
ACTA2: Actin, a1pha2, smooth muscle, aorta BCA: Bicinchoninic acid
Such a dressing can be applied to an injury / a wound during the healing step in order to prevent or reduce the appearance of keloids or hypertrophic scars.
Thus it can be for use in the treatment and/or prevention and/or attenuation, notably in the prevention, of fibrosis diseases, in particular excessive scars such as keloids or hypertrophic scars.
It is thus preferably sterile.
Such a dressing can be more particularly a pressure dressing.
The pad, compress or sponge can be made of various materials, preferably absorbent materials, such as cotton, gauze, a porous polymer material, or a combination thereof, notably cotton and/or gauze.
It can also comprise a bandage or adhesive means in order to maintain the pad or compress in close contact with the injury or wound.
The present invention relates also to a dressing as defined above for use in the treatment and/or prevention and/or attenuation of fibrosis diseases, in particular excessive scars such as keloids or hypertrophic scars.
The present invention relates also to the use of a dressing as defined above for the manufacture of a medicament intended for the treatment and/or prevention and/or attenuation of fibrosis diseases, in particular excessive scars such as keloids or hypertrophic scars.
The present invention relates also to the use of as defined above in the treatment and/or prevention and/or attenuation of fibrosis diseases, in particular excessive scars such as keloids or hypertrophic scars.
The present invention relates also to a method of treating and/or preventing and/or attenuating fibrosis diseases, in particular excessive scars such as keloids or hypertrophic scars, comprising the application to a person in need thereof of a dressing as defined above.
This dressing can be used in combination with, and more particular after, a laser or surgical treatment. Indeed, a patient suffering from a fibrosis disease, in particular excessive scars such as keloids or hypertrophic scars, can be first treated with laser or by surgery to eliminate the excess fibrous connective tissue and then a dressing 5 according to the invention can be applied on the wound during its healing in order to prevent the reappearance of the excess fibrous connective tissue.
The present invention is illustrated by the following non-limitative examples.
The following abbreviations have been used in the examples:
ACTA2: Actin, a1pha2, smooth muscle, aorta BCA: Bicinchoninic acid
15 COL1A: Collagen, type I, alpha 1 COL3A1: Collagen, type III, alpha 1 COL5A1: Collagen, type V, alpha 1 COL8A1: Collagen, type VIII, alpha 1 DCN: Decorin DMEM: Dulbecco's modified Eagle's medium DPT: Dermatopontin ECM: Extracellular matrix ELN: Elastin FBLN5: Fibulin 5 FCS: Fetal calf serum KF: Keloid fibroblasts LEPR: Leptin receptor MMP: Matrix metalloproteinase MMPl: Matrix metallopeptidase 1 (interstitial collagenase) MMP3: Matrix metallopeptidase 3 (stromelysin, progelatinase) mRNA: Messenger ribonucleic acid NF: Normal fibroblasts
16 PBS: Phosphate buffered saline PCOLCE: Procollagen C-endopeptidase enhancer PCR: Polymerase Chain Reaction RT-qPCR: Reverse Transcription quantitative PCR
sem: standard error of the mean TGF-13: Transforming growth factor beta TFPI2: Tissue factor pathway inhibitor 2 TMB: 3,3 ',5 ,5 '-Tetramethylbenzidine TP53: Tumor protein p53 Compounds 1, 2, 3 and 4 used in the examples below were prepared as described in W02015/140178.
During excessive scar formation, a dysfunction of the healing process is observed, leading to an excessive matrix synthesis and/or deficient matrix degradation and remodeling.
In the present invention, the effect of CF2 glycopeptide of formula I was evaluated on the expression of a panel of genes that are involved in mechanism of reducing excessive scars. The study was performed on normal and aged human fibroblasts at mRNA
levels.
An additional study was performed on normal and keloid fibroblasts at protein levels.
In normal human dermal fibroblasts, compound 1 can inhibit the expression of genes implicated in extracellular matrix (ECM) synthesis (COL1A1, COL3A1, ELN, COL5A1, COL8A1, DCN, DPT, FBLN5, PCOLCE) and can stimulate the expression of genes implicated in ECM degradation (MMP1, MMP3 and TFPI2). The results are presented in Table 1.
Besides keloid scars are characterized by a collection of atypical fibroblasts with excessive deposition of extracellular matrix components. An overproduction and accumulation of collagen (increased type I/III collagen ratio) and elastin, as well as a low level of matrix metalloproteinases MMP1 and MMP3 have been mainly observed in keloids (HistoL Histopathol. 2015, 30, 1033-1057).
sem: standard error of the mean TGF-13: Transforming growth factor beta TFPI2: Tissue factor pathway inhibitor 2 TMB: 3,3 ',5 ,5 '-Tetramethylbenzidine TP53: Tumor protein p53 Compounds 1, 2, 3 and 4 used in the examples below were prepared as described in W02015/140178.
During excessive scar formation, a dysfunction of the healing process is observed, leading to an excessive matrix synthesis and/or deficient matrix degradation and remodeling.
In the present invention, the effect of CF2 glycopeptide of formula I was evaluated on the expression of a panel of genes that are involved in mechanism of reducing excessive scars. The study was performed on normal and aged human fibroblasts at mRNA
levels.
An additional study was performed on normal and keloid fibroblasts at protein levels.
In normal human dermal fibroblasts, compound 1 can inhibit the expression of genes implicated in extracellular matrix (ECM) synthesis (COL1A1, COL3A1, ELN, COL5A1, COL8A1, DCN, DPT, FBLN5, PCOLCE) and can stimulate the expression of genes implicated in ECM degradation (MMP1, MMP3 and TFPI2). The results are presented in Table 1.
Besides keloid scars are characterized by a collection of atypical fibroblasts with excessive deposition of extracellular matrix components. An overproduction and accumulation of collagen (increased type I/III collagen ratio) and elastin, as well as a low level of matrix metalloproteinases MMP1 and MMP3 have been mainly observed in keloids (HistoL Histopathol. 2015, 30, 1033-1057).
17 That is why the expression of genes implicated in extracellular matrix generation, as collagen 1, collagen 3 and elastin, and in extracellular matrix degradation, as MMP1, was particularly studied in fibroblasts cultures.
Compounds 1, 2, 3 and 4 can modulate gene profile in a way to avoid the ECM
product deposit by decreasing the expression of COL1A1, COL3A1 and ELN; and also by increasing the expression of MMP1 in aged human dermal fibroblasts. The results are presented in Table 2.
In addition, it has been showed that expression of transforming growth factor impact the formation of keloids. The expression of TGF-I3 receptors TGF-I3R1 and TGF-I3R2 are higher in keloid fibroblasts compared to normal human dermal fibroblasts (Plast. Reconstr. Surg. 2001, 108, 423-429). Besides, leptin also play a major role in wound healing process and it has been shown that leptin is overexpressed in keloids and hypertrophic scars (AppL Immunohistochem. Mol. Morphol. 2016, 24, 296-306).
Thus, LEPR and TGFI3R2 mRNA expression was measured in normal fibroblasts. The expression of these genes involved in cell proliferation was reduced in the presence of compound 1. The results are presented in Table 3.
Then, compound 1 also decreases the expression of the ACTA2 gene encoding the alpha smooth muscle actin which has been described to increase in fibrosis/hypertrophic scar or keloid. The results are presented in Table 4.
Finally, to support the results obtained at mRNA levels, an evaluation of compound 1 on the production of proteins, particularly on collagen I and collagen III, in culture of human normal fibroblasts (NF) and keloid fibroblasts (KF) has been performed.
In accordance with what is described in the literature an increased collagen I
/collagen III ratio was observed in keloids fibroblasts compared to normal fibroblasts control. The results show that, in the presence of compound 1, the collagen I/collagen III
ratio in KF
decreased up to a value close to NF control. Compound 1 inhibits the synthesis of collagens I and III in fibroblasts obtained from keloid scars. The results are presented in Table 5.
Compounds 1, 2, 3 and 4 can modulate gene profile in a way to avoid the ECM
product deposit by decreasing the expression of COL1A1, COL3A1 and ELN; and also by increasing the expression of MMP1 in aged human dermal fibroblasts. The results are presented in Table 2.
In addition, it has been showed that expression of transforming growth factor impact the formation of keloids. The expression of TGF-I3 receptors TGF-I3R1 and TGF-I3R2 are higher in keloid fibroblasts compared to normal human dermal fibroblasts (Plast. Reconstr. Surg. 2001, 108, 423-429). Besides, leptin also play a major role in wound healing process and it has been shown that leptin is overexpressed in keloids and hypertrophic scars (AppL Immunohistochem. Mol. Morphol. 2016, 24, 296-306).
Thus, LEPR and TGFI3R2 mRNA expression was measured in normal fibroblasts. The expression of these genes involved in cell proliferation was reduced in the presence of compound 1. The results are presented in Table 3.
Then, compound 1 also decreases the expression of the ACTA2 gene encoding the alpha smooth muscle actin which has been described to increase in fibrosis/hypertrophic scar or keloid. The results are presented in Table 4.
Finally, to support the results obtained at mRNA levels, an evaluation of compound 1 on the production of proteins, particularly on collagen I and collagen III, in culture of human normal fibroblasts (NF) and keloid fibroblasts (KF) has been performed.
In accordance with what is described in the literature an increased collagen I
/collagen III ratio was observed in keloids fibroblasts compared to normal fibroblasts control. The results show that, in the presence of compound 1, the collagen I/collagen III
ratio in KF
decreased up to a value close to NF control. Compound 1 inhibits the synthesis of collagens I and III in fibroblasts obtained from keloid scars. The results are presented in Table 5.
18 In conclusion, results obtained at mRNA and proteins levels indicate that compounds of formula I can treat and/or prevent and/or attenuate fibrosis diseases, in particular hypertrophic scars and keloids.
General Experimental Procedure 1. Effects of compounds 1, 2, 3, 4 on expression of genes involved in ECM
synthesis or degradation, in normal or aged fibroblast culture (Analysis of mRNA
expression profile by RT-qPCR) In the present study, the transcriptional effects (modulation of gene expression) of compounds 1, 2, 3, 4 was evaluated on "aged" human dermal fibroblasts (Hayflick model) and normal human dermal fibroblasts (NHDF) in order to assess their potential effect.
More specifically, the effects of the compound on "aged" fibroblasts and NHDF
were evaluated using RT-qPCR technology. Extracted mRNAs were analyzed using a PCR
for the analysis of target genes (including housekeeping genes) selected for their importance in dermal fibroblast physiology.
Materials and methods a) Biological model - Subculturing: Human dermal fibroblasts were grown in culture medium composed of DMEM supplemented with L-glutamine (2 mM), Penicillin (50 U/ml), Streptomycin (50 ug/m1) and Fetal calf serum (FCS) 10% in 37 C and 5% CO2 incubator.
- Assay: Cells were used at the 7th passage (normal fibroblasts) or the 17th passage (aged fibroblasts). The assay medium was composed of DMEM supplemented with L-glutamine (2 mM), Penicillin (50 U/ml), Streptomycin (50) ug/m1 and FCS 1%.
b) Test compounds An intermediate solution of compounds 1, 2, 3, 4 was prepared in assay medium at concentration 100 mg/ml (pH =7.4) to be tested at 94mM or 34mM in normal or aged fibroblasts culture.
General Experimental Procedure 1. Effects of compounds 1, 2, 3, 4 on expression of genes involved in ECM
synthesis or degradation, in normal or aged fibroblast culture (Analysis of mRNA
expression profile by RT-qPCR) In the present study, the transcriptional effects (modulation of gene expression) of compounds 1, 2, 3, 4 was evaluated on "aged" human dermal fibroblasts (Hayflick model) and normal human dermal fibroblasts (NHDF) in order to assess their potential effect.
More specifically, the effects of the compound on "aged" fibroblasts and NHDF
were evaluated using RT-qPCR technology. Extracted mRNAs were analyzed using a PCR
for the analysis of target genes (including housekeeping genes) selected for their importance in dermal fibroblast physiology.
Materials and methods a) Biological model - Subculturing: Human dermal fibroblasts were grown in culture medium composed of DMEM supplemented with L-glutamine (2 mM), Penicillin (50 U/ml), Streptomycin (50 ug/m1) and Fetal calf serum (FCS) 10% in 37 C and 5% CO2 incubator.
- Assay: Cells were used at the 7th passage (normal fibroblasts) or the 17th passage (aged fibroblasts). The assay medium was composed of DMEM supplemented with L-glutamine (2 mM), Penicillin (50 U/ml), Streptomycin (50) ug/m1 and FCS 1%.
b) Test compounds An intermediate solution of compounds 1, 2, 3, 4 was prepared in assay medium at concentration 100 mg/ml (pH =7.4) to be tested at 94mM or 34mM in normal or aged fibroblasts culture.
19 c) Cultures and treatments Aged or normal fibroblasts were seeded in 12-well or 24-well plates and cultured for 24 to 48 hours in culture medium. The medium was then removed and replaced by assay medium containing the test compound (treated) or not (control) and the cells were incubated for 24 hours. All experimental conditions were performed in n=3. At the end of incubation, the cells were washed in a phosphate buffered saline (PBS) solution and immediately frozen at -80 C.
d) Differential gene expression analysis by RT-qPCR method The expression of markers was analyzed using RT-qPCR method on mRNA extracted from the cell monolayers of each experimental condition (before RNA
extraction, the replicates of the same experimental condition were pooled). The analysis of transcripts was performed in n=2 using a PCR array.
Reverse Transcription: Total RNA was extracted from each sample using TriPure Isolation Reagent or NucleoSpin0 RNA Plus kit (Macherey-Nagel) according to the supplier's instructions. The amount and quality of RNA were evaluated using electrophoresis (Bioanalyzer 2100, Agilent technologies). Potential contaminant traces of genomic DNA were removed using the DNAfree system (Ambion). The complementary DNA (cDNA) was synthetized by reverse transcription of total RNA
in presence of oligo(dT) and "Transcriptor Reverse Transcriptase" (Roche).
Quantification of cDNA was performed using a spectrophotometer (Nanovue, GE Healthcare) and cDNA quantities were adjusted.
Quantitative PCR: The PCRs (Polymerase Chain Reactions) were performed using the "LightCycler0" system (Roche Molecular System Inc.) according to the supplier's instructions. The reaction mix (10 1 final) was prepared as follows: 2.5 1 of cDNA, primers (forward and reverse), reagent mix containing taq DNA polymerase, SYBR
Green I and MgCl2.
Data management of quantitative PCR: Raw data were analyzed using Microsoft Excel software. The incorporation of fluorescence in amplified DNA was continuously measured during the PCR cycles. This resulted in a "fluorescence intensity" versus "PCR cycle" plot allowing the evaluation of a relative expression (RE) value for each marker.
The value selected for RE calculations is the "output point" (Ct) of the fluorescence 5 curve. For a considered marker, the highest is the cycle number, the lowest is the mRNA quantity.
l f number o cyces The RE value was calculated with the formula: (1/2 ) x 106.
Two housekeeping genes RPS28 and GAPDH were used for data normalization since 10 their expression is constitutive and theoretically stable. The mean relative expression of housekeeping genes was calculated for all test conditions. The level of expression of the target markers was compared to the mean expression level of these 2 markers for all test conditions (% control mean HK).
15 Classification of effects ("treated" conditions versus "normal control"
or "aged control'):
For a standardized interpretation, the following table was used:
Relative expression Classification of effects (% of control) > 300% Strong stimulation > 200% and < 300% Stimulation >30% and < 50% Inhibition <30% Strong inhibition II. Evaluation of the effects of compound 1 on collagen expression in human keloid
d) Differential gene expression analysis by RT-qPCR method The expression of markers was analyzed using RT-qPCR method on mRNA extracted from the cell monolayers of each experimental condition (before RNA
extraction, the replicates of the same experimental condition were pooled). The analysis of transcripts was performed in n=2 using a PCR array.
Reverse Transcription: Total RNA was extracted from each sample using TriPure Isolation Reagent or NucleoSpin0 RNA Plus kit (Macherey-Nagel) according to the supplier's instructions. The amount and quality of RNA were evaluated using electrophoresis (Bioanalyzer 2100, Agilent technologies). Potential contaminant traces of genomic DNA were removed using the DNAfree system (Ambion). The complementary DNA (cDNA) was synthetized by reverse transcription of total RNA
in presence of oligo(dT) and "Transcriptor Reverse Transcriptase" (Roche).
Quantification of cDNA was performed using a spectrophotometer (Nanovue, GE Healthcare) and cDNA quantities were adjusted.
Quantitative PCR: The PCRs (Polymerase Chain Reactions) were performed using the "LightCycler0" system (Roche Molecular System Inc.) according to the supplier's instructions. The reaction mix (10 1 final) was prepared as follows: 2.5 1 of cDNA, primers (forward and reverse), reagent mix containing taq DNA polymerase, SYBR
Green I and MgCl2.
Data management of quantitative PCR: Raw data were analyzed using Microsoft Excel software. The incorporation of fluorescence in amplified DNA was continuously measured during the PCR cycles. This resulted in a "fluorescence intensity" versus "PCR cycle" plot allowing the evaluation of a relative expression (RE) value for each marker.
The value selected for RE calculations is the "output point" (Ct) of the fluorescence 5 curve. For a considered marker, the highest is the cycle number, the lowest is the mRNA quantity.
l f number o cyces The RE value was calculated with the formula: (1/2 ) x 106.
Two housekeeping genes RPS28 and GAPDH were used for data normalization since 10 their expression is constitutive and theoretically stable. The mean relative expression of housekeeping genes was calculated for all test conditions. The level of expression of the target markers was compared to the mean expression level of these 2 markers for all test conditions (% control mean HK).
15 Classification of effects ("treated" conditions versus "normal control"
or "aged control'):
For a standardized interpretation, the following table was used:
Relative expression Classification of effects (% of control) > 300% Strong stimulation > 200% and < 300% Stimulation >30% and < 50% Inhibition <30% Strong inhibition II. Evaluation of the effects of compound 1 on collagen expression in human keloid
20 fibroblasts culture Materials and methods a) Biological model Primary cultures of keloid fibroblasts (KF) and normal fibroblasts (NF) were obtained from operative wastes (keloid and abdominoplasty). After thawing, cells were grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% of fetal calf serum, 40 mg/1 of gentamicin and 2 mg/1 of fungizone (DMEMc), in an incubator at
21 37 C, 5% CO2. Culture medium was changed twice a week and cells were subcultured by trypsinization when confluence was reached. Cells were used under 10 passages.
b) Tested compound Compound 1 was directly diluted in culture medium at 5mg/ml.
c) Cell culture and collect Fibroblasts were seeded in 6 wells culture plate at the concentration of 0.08.106 cells/well (n = 6). After 48 hours of culture, wells were washed with 3 ml of PBS. 2 ml of each solution of tested compound were added per wells. Plates were then incubated at 37 C with 5% CO2. After 48 hours of culture, 4x200 pl of supernatant were collected in Eppendorf vials containing 20 pl of protease inhibitor cocktail and stored at -80 C until collagen synthesis analysis. The monolayer cells were then washed with 3 ml of PBS
and 250 pl of 0.1N NaOH were added. After 10 minutes supernatants were removed into an Eppendorf and stored at -20 C until proteins analysis.
d) Evaluation of collagen synthesis The synthetized collagen quantity is expressed as the ratio of quantity of collagen vs quantity of total proteins in the sample.
Evaluation of the quantity of total proteins in the sample: The quantity of total protein was determined using a biochemical test, the bicinchoninic acid assay (BCA
assay). The total protein concentration is exhibited by a color change of the sample solution from green to purple in proportion to protein concentration, which can then be measured using colorimetric techniques. Bicinchoninic acid (BCA) as soluble sodium salt in aqueous medium reacts in a stably, sensitive and highly specific manner with cuprous ions. Proteins react with cupric ions (issued from copper(II) sulfate) in an alkaline medium to produce cuprous ions. Then, two molecules of BCA with one cuprous ion react to form a purple complex which shows an absorption peak at 562 nm.
A standard curve (0-2 mg/ml) is established with a bovine serum albumin solution. 20 [Ll of each tested concentration of the standard or of the sample are placed in wells of a 96 well-plate, in duplicate. 200 pl of Pierce reagent (comprising BCA and copper(II)
b) Tested compound Compound 1 was directly diluted in culture medium at 5mg/ml.
c) Cell culture and collect Fibroblasts were seeded in 6 wells culture plate at the concentration of 0.08.106 cells/well (n = 6). After 48 hours of culture, wells were washed with 3 ml of PBS. 2 ml of each solution of tested compound were added per wells. Plates were then incubated at 37 C with 5% CO2. After 48 hours of culture, 4x200 pl of supernatant were collected in Eppendorf vials containing 20 pl of protease inhibitor cocktail and stored at -80 C until collagen synthesis analysis. The monolayer cells were then washed with 3 ml of PBS
and 250 pl of 0.1N NaOH were added. After 10 minutes supernatants were removed into an Eppendorf and stored at -20 C until proteins analysis.
d) Evaluation of collagen synthesis The synthetized collagen quantity is expressed as the ratio of quantity of collagen vs quantity of total proteins in the sample.
Evaluation of the quantity of total proteins in the sample: The quantity of total protein was determined using a biochemical test, the bicinchoninic acid assay (BCA
assay). The total protein concentration is exhibited by a color change of the sample solution from green to purple in proportion to protein concentration, which can then be measured using colorimetric techniques. Bicinchoninic acid (BCA) as soluble sodium salt in aqueous medium reacts in a stably, sensitive and highly specific manner with cuprous ions. Proteins react with cupric ions (issued from copper(II) sulfate) in an alkaline medium to produce cuprous ions. Then, two molecules of BCA with one cuprous ion react to form a purple complex which shows an absorption peak at 562 nm.
A standard curve (0-2 mg/ml) is established with a bovine serum albumin solution. 20 [Ll of each tested concentration of the standard or of the sample are placed in wells of a 96 well-plate, in duplicate. 200 pl of Pierce reagent (comprising BCA and copper(II)
22 sulfate) were added and the plate is incubated for 30 minutes at 37 C.
Absorbance is read immediately at 550 nm (Spectrophotometer Multiscan Ex, Thermo). The standard curve is drawn and the sample protein concentration is determined with this curve. The results are expressed in mg protein/ml.
Evaluation of collagen I synthesis: Collagen I synthesis was evaluated by Enzyme-linked immunosorbent assay with an ELISA kit (USCN SEA571Hu, Euromedex). The assay was performed according to the supplier's instructions. To summarize, the microtiter plate provided in the kit is pre-coated with an antibody specific to collagen I.
Standard or samples are added to the wells with a biotin-conjugated antibody specific to collagen I. Next, avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. After TMB substrate solution is added, only those wells that contain collagen I, biotin-conjugated antibody and enzyme-conjugated avidin will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of sulfuric acid solution and the color change is measured spectrophotometrically at 450 nm. The concentration of collagen I in the samples is then determined by comparing the optical density of the samples to the standard curve. The results were expressed as pg of collagen I by mg of proteins.
Evaluation of collagen III synthesis: Collagen III synthesis is performed by Enzyme-linked immunosorbent assay with an ELISA kit (USCN SEA576Hu, Euromedex). The assay was performed according to the supplier's instructions. To summarize, the microtiter plate provided in the kit is pre-coated with an antibody specific to collagen III. Standard or samples are then added to the wells with a biotin-conjugated antibody specific to collagen III. Next, avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. After TMB substrate solution is added, only those wells that contain collagen III, biotin-conjugated antibody and enzyme-conjugated avidin will exhibit a change in color. The enzyme- substrate reaction is terminated by the addition of sulfuric acid solution and the color change is measured spectrophotometrically at 450 nm. The concentration of collagen III in the samples is then determined by comparing the optical density of the samples to the standard curve.
The results were expressed as ng of collagen III by mg of proteins.
Absorbance is read immediately at 550 nm (Spectrophotometer Multiscan Ex, Thermo). The standard curve is drawn and the sample protein concentration is determined with this curve. The results are expressed in mg protein/ml.
Evaluation of collagen I synthesis: Collagen I synthesis was evaluated by Enzyme-linked immunosorbent assay with an ELISA kit (USCN SEA571Hu, Euromedex). The assay was performed according to the supplier's instructions. To summarize, the microtiter plate provided in the kit is pre-coated with an antibody specific to collagen I.
Standard or samples are added to the wells with a biotin-conjugated antibody specific to collagen I. Next, avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. After TMB substrate solution is added, only those wells that contain collagen I, biotin-conjugated antibody and enzyme-conjugated avidin will exhibit a change in color. The enzyme-substrate reaction is terminated by the addition of sulfuric acid solution and the color change is measured spectrophotometrically at 450 nm. The concentration of collagen I in the samples is then determined by comparing the optical density of the samples to the standard curve. The results were expressed as pg of collagen I by mg of proteins.
Evaluation of collagen III synthesis: Collagen III synthesis is performed by Enzyme-linked immunosorbent assay with an ELISA kit (USCN SEA576Hu, Euromedex). The assay was performed according to the supplier's instructions. To summarize, the microtiter plate provided in the kit is pre-coated with an antibody specific to collagen III. Standard or samples are then added to the wells with a biotin-conjugated antibody specific to collagen III. Next, avidin conjugated to Horseradish Peroxidase (HRP) is added to each microplate well and incubated. After TMB substrate solution is added, only those wells that contain collagen III, biotin-conjugated antibody and enzyme-conjugated avidin will exhibit a change in color. The enzyme- substrate reaction is terminated by the addition of sulfuric acid solution and the color change is measured spectrophotometrically at 450 nm. The concentration of collagen III in the samples is then determined by comparing the optical density of the samples to the standard curve.
The results were expressed as ng of collagen III by mg of proteins.
23 Statistical analysis: Data are expressed as mean +/- sem. A variance analysis with one factor was performed for cytotoxicity study followed if necessary by a Fisher test. A
variance analysis with two factors was performed for synthesis study followed if necessary by a Fisher test. A p value less than 0.05 is considered significant.
Data management: To be able to compare the results, the collagen quantity is expressed as the ratio of quantity of collagen vs quantity of total proteins in the sample.
variance analysis with two factors was performed for synthesis study followed if necessary by a Fisher test. A p value less than 0.05 is considered significant.
Data management: To be able to compare the results, the collagen quantity is expressed as the ratio of quantity of collagen vs quantity of total proteins in the sample.
24 Table 1: Effect of compound 1 (at 94mM) on gene expression involved in ECM
synthesis and degradation in normal human dermal fibroblasts.
Normal fibroblasts Control Compound Genes %
Control Cycles Cycles Mean HK
14.25 17.03 COL1A1 _____________________________________________________________ 17 14.35 17.13 20.14 22.87 20.06 22.72 20.58 22.87 20.67 22.87 22.1 24.57 22.14 24.51 17.89 19.94 ECM synthesis/ ECM assembly DCN 29 17.91 19.89 21.86 24.18 21.95 24.14
synthesis and degradation in normal human dermal fibroblasts.
Normal fibroblasts Control Compound Genes %
Control Cycles Cycles Mean HK
14.25 17.03 COL1A1 _____________________________________________________________ 17 14.35 17.13 20.14 22.87 20.06 22.72 20.58 22.87 20.67 22.87 22.1 24.57 22.14 24.51 17.89 19.94 ECM synthesis/ ECM assembly DCN 29 17.91 19.89 21.86 24.18 21.95 24.14
25.47 27.17 25.35 27.16 23.11 24.21 FBLN5 _______________________________________________________________ 48 22.65 24.06 20.75 22.02 PCOLCE _____________________________________________________________ 49 20.84 22.04 20.87 16.24 20.77 16.24 22.9 20.88 ECM degradation MMP3 ________________________ 448 22.86 20.97 29.91 26.14 29.99 26.01 Up-regulated genes (arbitrary selection for stimulation): % >200 Down-regulated genes (arbitrary selection for inhibition): % <50 t.) o Table 2: Effect of compounds 1, 2, 3 and 4 (at 34mM) on gene expression involved in ECM synthesis and degradation in "aged" .
oe human dermal fibroblasts.
oe vi .6.
1-, "Aged" fibroblasts Control Compound 1 Compound 2 Compound 3 Compound 4 % %
Genes % Control % Control Cycles Cycles Control Cycles Control Cycles Cycles Mean HK Mean HK
Mean HK Mean HK
14.45 16.23 16.60 16.29 15.67 P
COL1A1 31 23 33 42 ' 14.51 16.16 16.70 16.01 15.73 , ECM synthesis/ 21.63 22.94 23.29 23.46 23.84 .
33 21 N, ECM assembly 21.65 23.09 23.44 23.21 23.85 N) , 27.83 29.89 29.97 28.99 29.72 .
, 21 .
27.52 30.08 30.21 29.28 30.04 20.82 17.53 17.14 18.93 18.33 ECM degradation MMP1 962 1341 20.78 17.60 17.13 18.81 18.35 Up-regulated genes (arbitrary selection for stimulation): % >200 Down-regulated genes (arbitrary selection for inhibition): % <50 IV
n ,-i ,.., =
--, =
=
=
,.., =
-,
oe human dermal fibroblasts.
oe vi .6.
1-, "Aged" fibroblasts Control Compound 1 Compound 2 Compound 3 Compound 4 % %
Genes % Control % Control Cycles Cycles Control Cycles Control Cycles Cycles Mean HK Mean HK
Mean HK Mean HK
14.45 16.23 16.60 16.29 15.67 P
COL1A1 31 23 33 42 ' 14.51 16.16 16.70 16.01 15.73 , ECM synthesis/ 21.63 22.94 23.29 23.46 23.84 .
33 21 N, ECM assembly 21.65 23.09 23.44 23.21 23.85 N) , 27.83 29.89 29.97 28.99 29.72 .
, 21 .
27.52 30.08 30.21 29.28 30.04 20.82 17.53 17.14 18.93 18.33 ECM degradation MMP1 962 1341 20.78 17.60 17.13 18.81 18.35 Up-regulated genes (arbitrary selection for stimulation): % >200 Down-regulated genes (arbitrary selection for inhibition): % <50 IV
n ,-i ,.., =
--, =
=
=
,.., =
-,
26 Table 3: Effect of compound 1 (at 94mM) on gene expression involved in cell proliferation in normal human dermal fibroblasts.
Normal fibroblasts Control Compound 1 Genes % Control Cycles Cycles Mean HK
Normal fibroblasts Control Compound 1 Genes % Control Cycles Cycles Mean HK
27.60 29.64
28.01 29.16 Cell proliferation 25.21 27.51 25.24 27.26 Up-regulated genes (arbitrary selection for stimulation) : % >200 Down-regulated genes (arbitrary selection for inhibition): % <50 Table 4: Effect of compound 1 (at 94mM) on gene expression involved in cytoskeletal integrity in normal human dermal fibroblasts.
Normal fibroblasts Control Compound 1 Genes % Control Cycles Cycles Mean HK
24.68 26.76 Cytoskeletal integrity ACTA2 28 24.83 26.87 Up-regulated genes (arbitrary selection for stimulation) : % >200 Down-regulated genes (arbitrary selection for inhibition): % <50 Table 5: Synthesis of Collagen I and Collagen III proteins in the presence or not of compound 1 (at 9.4mM) in normal and keloids fibroblasts.
Normal fibroblasts Keloids fibroblasts NF Control NF + compound 1 KF Control KF +
compound 1 Mean sem Mean sem Mean sem Mean sem Protein Collagen!
103.5 5.61 28.85*** 5.04 149.89*** 12.58 44.6ew 6.03 (pg/mg) Protein Collagen!!!
11.84 0.82 6.57*** 0.61 6.46*** 0.46 4.424 0.25 (ng/mg) Collagen!
Ratio 8.74.10-3 4.39.10-3 23.20.10-3 10.11.10-Collagen III
*** p<0.001 versus NF Control #
p<0.05 versus KF Control ### p<0.001 versus KF Control
Normal fibroblasts Control Compound 1 Genes % Control Cycles Cycles Mean HK
24.68 26.76 Cytoskeletal integrity ACTA2 28 24.83 26.87 Up-regulated genes (arbitrary selection for stimulation) : % >200 Down-regulated genes (arbitrary selection for inhibition): % <50 Table 5: Synthesis of Collagen I and Collagen III proteins in the presence or not of compound 1 (at 9.4mM) in normal and keloids fibroblasts.
Normal fibroblasts Keloids fibroblasts NF Control NF + compound 1 KF Control KF +
compound 1 Mean sem Mean sem Mean sem Mean sem Protein Collagen!
103.5 5.61 28.85*** 5.04 149.89*** 12.58 44.6ew 6.03 (pg/mg) Protein Collagen!!!
11.84 0.82 6.57*** 0.61 6.46*** 0.46 4.424 0.25 (ng/mg) Collagen!
Ratio 8.74.10-3 4.39.10-3 23.20.10-3 10.11.10-Collagen III
*** p<0.001 versus NF Control #
p<0.05 versus KF Control ### p<0.001 versus KF Control
Claims (18)
1. A compound of following formula I:
or a salt thereof, a solvate, a tautomer, a stereoisomer or a mixture of stereoisomers in any proportions, in particular a mixture of enantiomers, and particularly a racemate mixture, in which:
- n represents an integer from 1 to 6, - m represents 0 or 1, - p represents 0 or 1 - R represents H, F, CH3, CH2F, or CH2OH, - R1, R2 and R3 represent, independently from one another, H, F, or OH, - R4 represents a hydrogen, a halogen, or OH, - R6 and R7 represent, independently from each other, a hydrogen, a (C1-C6)alkyl, an aryl, or an ary1-(C1-C6)alkyl, for use in the treatment and/or prevention and/or attenuation of fibrosis diseases.
or a salt thereof, a solvate, a tautomer, a stereoisomer or a mixture of stereoisomers in any proportions, in particular a mixture of enantiomers, and particularly a racemate mixture, in which:
- n represents an integer from 1 to 6, - m represents 0 or 1, - p represents 0 or 1 - R represents H, F, CH3, CH2F, or CH2OH, - R1, R2 and R3 represent, independently from one another, H, F, or OH, - R4 represents a hydrogen, a halogen, or OH, - R6 and R7 represent, independently from each other, a hydrogen, a (C1-C6)alkyl, an aryl, or an ary1-(C1-C6)alkyl, for use in the treatment and/or prevention and/or attenuation of fibrosis diseases.
2. The compound for use according to claim 1, wherein fibrosis diseases are excessive scars.
3. The compound for use according to claim 2, wherein excessive scars are keloids or hypertrophic scars.
4. The compound for use according to any one of claims 1 to 3, wherein it has one of the following formulas (Ia), (Ib), (Ic):
5. The compound for use according to any one of claims 1 to 4, wherein n represents an integer from 2 to 6, notably from 3 to 5, such as 4.
6. The compound for use according to any one of claims 1 to 5, wherein R
represents a CH2OH group.
represents a CH2OH group.
7. The compound for use according to any one of claims 1 to 6, wherein R1, R2 and R3 each represent a OH group.
8. The compound for use according to any one of claims 1 to 7, wherein R4 represents a OH group.
9. The compound for use according to any one of claims 1 to 8, wherein R6 and R7 represent, independently from each other, a (C1-C6)alkyl, an aryl or an aryl-(C1-C6)alkyl; more particularly a (C1-C6)alkyl such as a methyl.
10. The compound for use according to any one of claims 1 to 9, wherein it is chosen among the following compounds:
and the salts and/or solvates thereof.
and the salts and/or solvates thereof.
11. A pharmaceutical composition comprising at least one compound of following formula I:
or a salt thereof, a solvate, a tautomer, a stereoisomer or a mixture of stereoisomers in any proportions, in particular a mixture of enantiomers, and particularly a racemate mixture, in which:
- n represents an integer from 1 to 6, - m represents 0 or 1, - p represents 0 or 1 - R represents H, F, CH3, CH2F, or CH2OH, - R1, R2 and R3 represent, independently from one another, H, F, or OH, - R4 represents a hydrogen, a halogen, or OH, - R6 and R7 represent, independently from each other, a hydrogen, a (C1-C6)alkyl, an aryl, or an aryl-(C1-C6)alkyl, and at least one pharmaceutically acceptable excipient, for use in the treatment and/or prevention and/or attenuation of fibrosis diseases
or a salt thereof, a solvate, a tautomer, a stereoisomer or a mixture of stereoisomers in any proportions, in particular a mixture of enantiomers, and particularly a racemate mixture, in which:
- n represents an integer from 1 to 6, - m represents 0 or 1, - p represents 0 or 1 - R represents H, F, CH3, CH2F, or CH2OH, - R1, R2 and R3 represent, independently from one another, H, F, or OH, - R4 represents a hydrogen, a halogen, or OH, - R6 and R7 represent, independently from each other, a hydrogen, a (C1-C6)alkyl, an aryl, or an aryl-(C1-C6)alkyl, and at least one pharmaceutically acceptable excipient, for use in the treatment and/or prevention and/or attenuation of fibrosis diseases
12. The pharmaceutical composition for use according to claim 11, wherein fibrosis diseases are excessive scars.
13. The pharmaceutical composition for use according to claim 12, wherein excessive scars are keloids or hypertrophic scars.
14. The pharmaceutical composition for use according to any one of claims 11 to 13, wherein the compound of formula I is as defined in any one of claims 4 to 10.
15. The pharmaceutical composition for use according to any one of claims 11 to 14, for topical use in combination with, and more particular after, a laser or surgical treatment.
16. A dressing comprising a pad, compress or sponge impregnated with a pharmaceutical composition comprising at least one compound of following formula I:
or a salt thereof, a solvate, a tautomer, a stereoisomer or a mixture of stereoisomers in any proportions, in particular a mixture of enantiomers, and particularly a racemate mixture, in which:
- n represents an integer from 1 to 6, - m represents 0 or 1, - p represents 0 or 1 - R represents H, F, CH3, CH2F, or CH2OH, - R1, R2 and R3 represent, independently from one another, H, F, or OH, - R4 represents a hydrogen, a halogen, or OH, - R6 and R7 represent, independently from each other, a hydrogen, a (C1-C6)alkyl, an aryl, or an aryl-(C1-C6)alkyl, and at least one pharmaceutically acceptable excipient.
or a salt thereof, a solvate, a tautomer, a stereoisomer or a mixture of stereoisomers in any proportions, in particular a mixture of enantiomers, and particularly a racemate mixture, in which:
- n represents an integer from 1 to 6, - m represents 0 or 1, - p represents 0 or 1 - R represents H, F, CH3, CH2F, or CH2OH, - R1, R2 and R3 represent, independently from one another, H, F, or OH, - R4 represents a hydrogen, a halogen, or OH, - R6 and R7 represent, independently from each other, a hydrogen, a (C1-C6)alkyl, an aryl, or an aryl-(C1-C6)alkyl, and at least one pharmaceutically acceptable excipient.
17. A dressing according to claim 16, for use in the treatment and/or prevention and/or attenuation of fibrosis diseases, in particular excessive scars such as keloids or hypertrophic scars.
18. The dressing for use according to claim 17, for use in combination with, and more particular after, a laser or surgical treatment.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/IB2017/000207 WO2018138541A1 (en) | 2017-01-30 | 2017-01-30 | Glycopeptide derivatives for use in the treatment and/or prevention and/or attenuation of fibrosis diseases |
Publications (2)
Publication Number | Publication Date |
---|---|
CA3051652A1 true CA3051652A1 (en) | 2018-08-02 |
CA3051652C CA3051652C (en) | 2023-11-28 |
Family
ID=58264567
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA3051652A Active CA3051652C (en) | 2017-01-30 | 2017-01-30 | Glycopeptide derivatives for use in the treatment and/or prevention and/or attenuation of fibrosis diseases |
Country Status (4)
Country | Link |
---|---|
US (1) | US10744181B2 (en) |
EP (1) | EP3573621B9 (en) |
CA (1) | CA3051652C (en) |
WO (1) | WO2018138541A1 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2022157233A1 (en) | 2021-01-20 | 2022-07-28 | Tfchem | Cyclic glycoaminoacid derivatives |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2878851B1 (en) * | 2004-12-02 | 2007-02-09 | Inst Nat Sciences Appliq | GEM-DIFLUORINE C-GLYCOPEPTIDE COMPOUNDS, THEIR PREPARATION AND THEIR USE IN CRYOPURURGY AND / OR CRYOPRESERVATION |
FR2900405B1 (en) * | 2006-04-27 | 2013-11-29 | Inst Nat Sciences Appliq | NOVEL MONOFLUORINE C-GLYCOSIDE COMPOUNDS, PROCESSES FOR THEIR PREPARATION AND THEIR APPLICATIONS |
FR2900656A1 (en) * | 2006-05-03 | 2007-11-09 | Inst Nat Sciences Appliq | GEM-DIFLUORINE C-GLYCOPEPTIDE COMPOUNDS, THEIR PREPARATION AND THEIR USE, IN PARTICULAR FOR THE PRESERVATION OF BIOLOGICAL MATERIALS |
JP6629285B2 (en) | 2014-03-17 | 2020-01-15 | テーエフケム | Glycopeptide derivatives for preservation and protection of biomaterials and microorganisms |
-
2017
- 2017-01-30 CA CA3051652A patent/CA3051652C/en active Active
- 2017-01-30 EP EP17709784.7A patent/EP3573621B9/en active Active
- 2017-01-30 WO PCT/IB2017/000207 patent/WO2018138541A1/en unknown
- 2017-01-30 US US16/482,040 patent/US10744181B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
EP3573621B1 (en) | 2021-02-24 |
US20190388501A1 (en) | 2019-12-26 |
EP3573621A1 (en) | 2019-12-04 |
US10744181B2 (en) | 2020-08-18 |
WO2018138541A1 (en) | 2018-08-02 |
EP3573621B9 (en) | 2021-08-25 |
CA3051652C (en) | 2023-11-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10231992B2 (en) | Antioxidant composition | |
US20080214669A1 (en) | Composition and Method For Treating Hyperpigmented Skin | |
KR20030009454A (en) | SKIN TISSUE REGENERATION PROMOTERS COMPRISING GINSENOSIDE Rb1 | |
KR20190042883A (en) | Composition for skin and fur of companion animal | |
KR100973221B1 (en) | Novel use of Panduratin A or derivatives thereof | |
CA3051652C (en) | Glycopeptide derivatives for use in the treatment and/or prevention and/or attenuation of fibrosis diseases | |
EP3384905B1 (en) | Composition for preventing or ameliorating hypersensitive skin comprising cedrol or derivatives thereof, or pharmaceutically acceptable salts thereof | |
KR102206017B1 (en) | Pharmaceutical composition for treating skin fibrosis comprising PARP1 inhibitor | |
US11357739B2 (en) | Pimarane diterpenoids for use in wound healing and angiogenesis | |
ES2909243T3 (en) | Salvia haenkei extract as an active agent in re-epithelialization and tissue healing processes | |
WO2007081190A1 (en) | Novel use of 1,2,3,4,6-penta-o-galloyl-beta-d-glucose | |
AU2016305746A1 (en) | Method of wound healing | |
KR20090113614A (en) | Cosmetic composition comprising retinol derivatives | |
US11166982B2 (en) | Multi-type stem cell activation with nano silver | |
JP5926507B2 (en) | Method for producing matrix metalloprotease inhibitor, method for producing elastase inhibitor, method for producing hyaluronidase inhibitor, and method for producing a skin external preparation for preventing wrinkles | |
CN109640974A (en) | Amide derivatives, the preparation method and use of more coffee acyl chinic acids | |
EP4225266A1 (en) | Compositions comprising silybum marianum extract as a senotherapeutic agent | |
WO2019151286A1 (en) | Topical dermatological composition | |
JP2007277119A (en) | Skin care preparation for external use | |
KR20130077953A (en) | Elastase inhibitors containing carnosic acid or derivatives thereof | |
TWI780699B (en) | Lactoferrin, derived peptides thereof and a use thereof for inhibiting and/or alleviating lipid synthesis | |
US20230127213A1 (en) | A topical composition comprising an extract of combined herbs comprising longanae arillus for the treatment or alleviation of skin ulcer and the use thereof | |
JP2004315492A (en) | Anti-aging cosmetic | |
CN110547975B (en) | Cosmetic material composition containing epipinoresinol | |
WO2021235275A1 (en) | Hyaluronic acid production promotor and collagen production promotor |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request |
Effective date: 20211221 |
|
EEER | Examination request |
Effective date: 20211221 |
|
EEER | Examination request |
Effective date: 20211221 |
|
EEER | Examination request |
Effective date: 20211221 |
|
EEER | Examination request |
Effective date: 20211221 |
|
EEER | Examination request |
Effective date: 20211221 |
|
EEER | Examination request |
Effective date: 20211221 |